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ABSTRACT

EXPLORE THE MURINE CARDIAC 20S PROTEASOMES:
MOLECULAR COMPOSITION AND REGULATION

Chenggong Zong
November, 2005

20S proteasome, essential component of protein degradation mechanism, is important to maintain
homeostasis. Its malfunctions have been associated with several pathological conditions. This
study presents an extensive study of murine cardiac 20S proteasome. Using biochemical methods,
20S proteasome have been purified to 95%. Proteomic study identified all 20S proteasome
subunits. Endogenous phosphorylation was also documented. Furthermore, several associating
kinases and phosphatase were identified. They regulated its activities. In PKCE over-expression
mice, 20S proteasome expression level was up-regulated, but its peptidase activities did not
increase.

as

crystallin were recruited to PKCE subproteome in the transgenic mice, which also

associated with 20S proteasome. This association was enhanced in the transgenic mice and has
been reported to inhibit 20S proteasome activities. It suggested as crystallin playa role in cardiac
20S proteasome regulation.
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CHAPTER I

GENERAL INTRODUCTION AND OVERVIEW
Literature Review
Proteasomes: An Essential Protein Degradation Machinery

The proteasome is a multi-meric protease complex. In the early days of proteasome study, it
was also known as a "multi catalytic proteinase", "macroxyproteinase" or "alkaline proteinase".
Further investigations proved all those names associate with the same protein complex. This is an
essential multimeric complex in cell biology. Its importance is highlighted by the fact that multiple
subunits of 20S proteasome are essential for yeast survival by knock down study (Heinemeyer,
Trondle et al. 1994). In the cell, the proteasome exists in multiple forms with different
sedimentation rates. One form of the proteasome with a sedimentation coefficient of 20S is the
minimal unit to have proteolytic activities and is called the 20S proteasome or core particle. The
core particle with a 700kDa regulatory protein complex (regulatory particle or PA700) binding on
either or both ends has a higher sedimentation coefficient of 26S and is named the 26S
proteasome, accordingly. Besides the 26S proteasome, the core particle can associate with other
regulatory protein/protein complex, which all contribute to the plasticity of the proteasome. These
include the 11 S regulatory complex and PA200. The recruitment of different regulatory complexes
to the core particle constitutes the variety of proteasome population within the cell, and the choice

of regulatory complexes is an important mechanism to tune the intracellular protein degradation
pathway (Coux, Tanaka et al. 1996; Bochtler, Ditzel et al. 1999; Glickman and Ciechanover 2002).
In depth understanding of the structure, function and regulation of this essential proteolytic
machinery is of great significance.

Mechanisms of Intracellular Protein Turn-over
One of the key features of life is the ability of maintaining homeostasis at the expense of
energy. Among the several important aspects of it, protein degradation is an indispensable part.
There are two main proteolytic systems, which execute routine protein catabolism in cells:
proteasome and lysosome pathways. In addition, there are Ca2+ dependent proteases and
apoptosis-related proteases, which are involved in specific signaling events (Debigare and
Price 2003).
Lysosome degradates membrane proteins and endocytosed proteins. These activities
correspond to cell membrane receptor regulation and cellular defense mechanism against
exotic proteins (Glickman and Ciechanover 2002). Mono-ubiquitination serves as tag for
selective endocytosis. Ubiquitin, as a shared player in both lysosomal proteins degradation
and proteasomal protein degradation, links these two protein degradation pathways.
Ubiquitin-dependent lysosomal degradation is recently reviewed (Bonifacino and Traub
2003).
Proteasome is responsible for turning over the majority of the cytosolic and nuclear proteins.
Proteins which are to be degraded, are tagged with poly-ubiquitin chains (poly-Ub) by the
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cooperation

of ubiquitin-activating

protein

(E1),

ubiquitin

carrier

proteins

(E2s)

and

ubiquitin-protein ligases (E3s and E4s) (Hershko and Ciechanover 1998). Poly-ubiquitinated
proteins are recognized by poly-Ub receptor in the 26S proteasome (Rpn10) or shuttle proteins
(such as Rad23). The poly-Ub is removed, and the tagged-proteins are degraded (Miller and
Gordon 2005) into peptides with an average length of 8-9 amino acids. These peptides are either
further digested by intracellular peptidases (e.g. Tripeptidyl-peptidase II) into amino acids to be
reused; or transported to the ER then represented by MHC I receptor as epitopes, playing
important role in immune response (Bochtler, Ditzel et al. 1999).

The Molecular Components and Structure of Proteasomes
Proteasome is in fact a collection of multi-meric proteinases, which are subunits of the
20S core particle. This core particle has been identified in all three branches of organism
society: archaeal bacteria, eubacteria and eukaryotes (Hoffman, Pratt et al. 1992; Zwickl,
Kleinz et al. 1994; To and Wang 1997; BochtJer, Ditzel et al. 1999; Shibahara, Kawasaki et al.
2002; Wang, Bozdech et al. 2003).
Archaei bacteria contain an ancient form of pro tea some core particle. This particle is
made up with two subunits with homology, a and B subunits. They form 4 stack of hapto-rings,
with a subunits, which constitute two outer rings and B subunits, which constitute two inner
rings (Bochtler, Ditzel et al. 1999). The B subunit is catalytically active, while the a subunit is
inactive. Crystallography shows both a and B subunits share the same conformation. Two
layers of 5 strands of the anti-parallel B -sheets form the core of both subunits, flanked by 2

3

anti-parallel

IX

helices on both ends, with an extra

which compares to the mature form of

IX

helix on the N-terminus of the

IX

subunits,

a subunit (Brannigan, Dodson et al. 1995; Oinonen and

Rouvinen 2000). N-terminal pre-peptide of

a subunit precursor is auto-proteolytically removed

during proteasome assembly, which generates mature

a subunit (Zwickl, Kleinz et al. 1994).

Both structural and biochemical studies suggest that proteasome subunits are distinct from
well-characterized cysteine proteases, serine proteases, asparic proteases and metalloproteases
(Lowe, Stock et al. 1995; Kisselev and Goldberg 2001). In fact, they belong to a family of proteins
called N-terminal nucleophile hydrolases (Ntns). Consistent with the name, N-terminal hydroxyl
group of proteins in this family serves as catalytic-active site. The extra N-terminal helix in the

IX

subunit explains its functional impotency (Brannigan, Dodson et al. 1995; Oinonen and Rouvinen
2000). Though catalytically inactive, the

IX

subunit plays key roles in proteasome assembly and

substrate specificity. The limited hole (13A) formed in the middle of heptametrical

IX

ring, only

allows certain proteins and peptides to access the proteolytic active sites, which is the structural
basis for substrate specificity (Zwickl, Kleinz et al. 1994). Only a few eubacterial contain
proteasomes, which are the result of horizontal transfer events (Bochtler, Ditzel et al. 1999).
Evolution diversifies proteasome subunits in eukaryotes. In yeast, there are 7 distinct
subunits and 7 distinct

a subunits. The classification as

IX

or

IX

a family member is both based

on the homology between these subunits and ancestor archaei bacteria subunits; and the spatial
arrangement of the subunit in 20S proteasome. Two copies of each subunits form a 28-mer 4
layers stack

(IX

1-7,

a 1-7,

IX

1-7,

a 1-7). Crystallography studies uncovered the spatial relationship
4

among different subunits and proposed an unequivocal nomenclature (Groll. Ditzel et al. 1997;
Groll. Koguchi et al. 2001). Both a subunits and /3 subunits of yeast proteasome have major
distinction with arch bacterial proteasomes. Among the 7 /3 subunits. 4 of them have
N-terminal truncation concurrent with proteasome maturation. and 3 out of these 4 are
proteolytically active. These proteolytic /3 subunits have distinct preferences towards peptide
substrates. The specificity of each subunit has been characterized by mutagenesis and inhibitor
analysis. The /3 1 subunit prefers to digest after acidic amino acids (caspase-like activity); /3 2
subunit prefers to digest after basic amino acids (trypsin-like activity); /3 5 prefers to digest after
hydrophobic amino acids (chymotrypsin-like activity). Unique fluorescent-tag recombinant
peptides were designed to study subunit specific peptidase activities (Leu-Leu-Glu-AMC for /3 1
subunit; Leu-8er-Thr-Arg-AMC for /3 2 subunit; Leu-Leu-Val-Tyr-AMC for /3 5 subunit) (Arendt
and Hochstrasser 1997; Heinemeyer. Fischer et al. 1997; Groll. Koguchi et al. 2001; Kisselev and
Goldberg 2001). Prepeptide removals are achieved autoproteolytically or executed by neighboring
subunits. Though removed upon maturation. these prepeptides play more important role than that
in archaebacteria. Delete mutation of yeast /3 5 presequence leads to cell death (Chen and
Hochstrasser 1996). N-terminal sequences of a subunits are also significantly different from the
archaebacteria counterpart. They occlude both ends of 208 proteasome. as a direct result of
elongated a

subunits in the N-terminal sequence. This leaves yeast 208 proteasome

predominantly in a latent form (Groll. Ditzel et al. 1997). There is a dynamic balance between the
active form and latent form of 208 proteasome. This explains why the 208 proteasome shows
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basal peptidase activities in an un-induced condition. This balance has be revealed by atomic
force microscopy (Osmulski and Gaczynska 2002; Furuike, Hirokawa et al. 2003). However, the
proteasome can be regulated to favor activated form by physiological activators (e.g. PA700,
Blm10) (Adams, Crotchett et al. 1998; Schmidt, Haas et al. 2005) or biochemical activators (e.g.
SDS, poly-lysine) (Shibatani and Ward 1995; Coux, Tanaka et al. 1996).
In mammals, the 20S proteasome is highly homologous to that of yeast. The sequences of
core particle subunits are conserved. Mammalian 20S proteasome also contains duplex of 7 Cl and
7 S subunits, organized in 4 stacks of hapto-rings. Both crystal graphic and
immuno-electron-microscopy studies show the spatial arrangement of subunits are also
conserved among species (Groll, Ditzel et al. 1997; Kopp, Hendil et al. 1997; Dahlmann,
Kopp et al. 1999; Unno, Mizushima et al. 2002). Both ends of mammalian 20S proteasome
are also occluded, which is consistent with the latency of it. The occlusion can be released by 19S
(homolog of PA700 in yeast) and PA200 (homolog of Blm10 yeast). Besides similarities, there are
increased complexities in mammalian proteasome to accommodate various functional
requirements. Three interferon-"y (IFN-"y) inducible proteolytic-active subunits (s 1i/Lmp2, S
2i/MECL-1, S5i/Lmp7) are coded and expressed upon stimulation, which is involved in immune
response. They would replace their constitutive expressing counterparts (S 1, S 2 and S 5
respectively) under IFN-"y regulation (Groettrup, Ruppert et al. 1995; Gaczynska, Goldberg et al.
1996). There is another regulatory complex inducible by IFN-"Y unique to mammalian 20S
proteasome, instead of yeast companion. 11S complex is an ATP-independent proteasome

6

activator involving in immune response (Groettrup, Ruppert et al. 1995; Rechsteiner, Realini et al.
2000). The co-existence of constitutive 20S proteasome subunits and their inducible counterparts
in mammals, raise the possibility of multiple "mixed" 20S proteasome forms in mammals. Though
existence of these forms has been shown, 20S proteasomes comprising either only constitutive
subunits (constitutive 20S) or only inducible subunits (immuno-proteasome) are the dominant
forms. Mutational studies show that

a subunit prepeptides dictate the preference. Compared to

constitutive proteasome, immuno-proteasome increases chymotrypsin-like and trypsin-like
activities and decreases caspase-like activity. The peptides, generated by immuno-proteasome,
have an average length longer than ones generated by constitutive-proteasome. A higher
percentage of peptides have a hydrophobic or basic N-terminal amino acid, too. These peptides
are better represented by MHC-1 receptor, which is consistence with an enhanced presentation of
epitopes. (Groettrup, Ruppert et al. 1995; Rechsteiner, Realini et al. 2000; Kuckelkorn, Ruppert et
al. 2002; De, Jayarapu et al. 2003; Kloetzel and Ossendorp 2004; Forster, Masterset al. 2005).

Ubiquitination and The E1-E4 Cascades
Ubiquitin (Ub) is a well-conserved 76 amino acid protein in eukaryotes which is always
synthesized in precursor forms either as a polypeptide containing multiple copies of Ub or
co-expressed with a ribosomal protein. De-ubiquitinases (DUBs) activate Ub precursor by
truncating it. C-terminal glycine carboxyl-group of Ub can be activated by E1 in an ATP
dependent manner. There is one E1 gene in both yeast and mouse. Activated Ub transfers
from E1 to E2 and then to lysine e -NH2 group of protein substrate forming an isopeptide bond
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as the result of the interplay between E2 and E3. There are tens of E2s and hundreds E3s
encoded in mammalian cells to achieve high specificity of Ub tagging. Besides lysine e -NH2 of
protein substrates, activated Ub can also tag e -NH2 of Ub (K29, K48, K63) linked to substrates,
thereby forming a poly-Ub chain. Poly-Ub chain linked by G76/K48 serves as a signal recognized
by 26S proteasome, which targets protein substrates to degradation. The biological context of
poly-Ub chain formed by G76/K29 or G76/K63 is less well understood. G76/K63 chain has been
reported to involved in DNA repair signaling (Hershko and Ciechanover 1998; Myung, Kim et al.
2001; Weissman 2001; Glickman and Ciechanover 2002). E4s are a special group of ubiquitin
ligases that selectively add extra Ub to preformed G76/K48 chain. U-box proteins function as E4 in
the cell (Hatakeyama and Nakayama 2003).
As opposed to poly-ubiquitination and sequentially degradation of nuclear and cytosolic
proteins, membrane proteins can be mono-ubiquitinated, which serves as a sorting signal for
vesicle trafficking process. Some of the vesicles merge with lysosome and membrane
proteins are degradated. This vesicle trafficking event has been reviewed recently (Katzmann,
Odorizzi et al. 2002; Horak 2003).
The specificity of ubiquitin-tagging procedure is exerted by hundreds of E3s. There are
two kinds of E3s: HECT domain containing E3s and Ring-finger domain containing E3s.
HECT domain containing E3s have a cysteine in the active site, which accepts activated Ub
from cognate E2s and passes it to its substrates. Ring-finger domain containing E3s have
zinc-finger domains instead of active site cysteine. They align cognate E2s and protein
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substrates and catalyze a direct transfer of Ub between them (Hershko and Ciechanover
1998; Deshaies 1999; Myung, Kim et al. 2001; Pickart 2001; 8chwechheimer 2004).
Deubiquitination is another key mechanism regulating the specificity of ubiquitin tagging
process. As mentioned previous, DUBs are required for maturation of ubiquitin. DUBs
associates with 268 proteasome removes poly-Ub chains from protein substrates. This
facilitates the translocation of substrate into the core particle and recycles ubiquitin.
Non-proteasome-associating DUBs remove non-specific ubiquitination and involves in vesicle
trafficking/receptor recycle. This partially explains proteins attached by poly-Ub of less than 4
Ub molecules are poor proteasome substrate. There are 5 families of DUBs reported. They
work inversely with E3 ligases to make sure proper substrates specificity (Ferrell, Wilkinson et
al. 2000; Amerik and Hochstrasser 2004).

The 20S Proteasomes Are Composed of Multiproteln Complexes

Native gel electrophoresis followed by fluorescent substrate overlay, showed the
existence of three species of 208 proteasome. Denaturing 8D8-PAGE analysis showed all
these species contain all subunits of 208 proteasome, while one form with an extra 30kDa
band, the other with an extra 160kDa band. 208 proteasome species containing either 30kDa
proteins or 200kDa protein showed enhanced peptidase activity. The 30kDa proteins are
highly suggested to be 118 subunit a and ~,while 160kDa protein is suggested to be PA200
(Hoffman, Pratt et al. 1992; To and Wang 1997). Purification of these different forms of 208
proteasome from cells proposes that 118 and PA200 regulate 208 proteasome activity in vivo.
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In vert$brates, existence of IFN- 'Y inducible subunits increases the complexity of
intracellular ~08 proteasome population. Immuno-proteasome is induced by IFN- 'Y and formed
via de novel> synthesis pathway. It has also been identified in other organs, instead of
immuno-spe¢ific organs, including the heart. Besides playing a key role in immune response,
other aspects of regulation evoked by immuno-proteasome induction are not clear (Bose,
Brooks et a1.12001; Kloetzel and Ossendorp 2004).
In a 20

~Iectrophoresis

(2DE) gel, purified 208 proteasome show more spots than expected

according to. the number of gene encoding 208 proteasome subunits (14 for yeast, 17 for
vertebrate). Mass spectrometry study show several proteasome subunits are each represented by
multiple spots on the 20 gel, respectively. This indicates the presence of extensive
post-translational modification regulations and the presence of a population of intracellular 208
proteasome

with

different

modifications

(Eleuteri,

Angeletti

et

al.

2000;

Froment,

Uttenweiler-Jc)seph et al. 2005; Hayter, Doherty et al. 2005).

Regulation of Proteasomal Activities by Post-translational Modification

As mentioned above, selective poly-ubiquitination defined substrate specificity of
ubiquitin-prot~asome

system; while the proteasome is only protein complex that turns over

ubiquitin tagg,d substrates. The 208 proteasome is a stable protein complex that needs a
long time to a$semble and has a long half-life (yang, Fruh et al. 1995; Meiners, Heyken et al.
2003). The

d~namic

regulation of 208 proteasome activity can only be executed by means

other than trarjlscription level. Post-translational modifications provide dynamic and reversible

10

ways to achieve it. In fact, multiple post-translational modifications have been uncovered at
20S

protea~ome,

including N-terminal acetylation (Coux, Tanaka et al. 1996; Bochtler, Ditzel

et al. 1999), phosphorylation (Castano, Mahillo et al. 1996; Mason, Murray et al. 1998; Bose,
Mason et all. 1999; Bose, Stratford et al. 2004), HNE modification (Okada, Wangpoengtrakul
et al.

1999)~

glycosylation (Zhang, Su et al. 2003; Zachara and Hart 2004) and poly-ADP

ribosylation (Ullrich, Reinheckel et al. 1999). They control proteasome assembly, subcellular
distribution, C/ctivity and substrate specificity.

Postulated Rrincipal Regulatory Sites of the 20S and 19S Subunits

20S pro~easome a subunits play an essential role in 20S proteasome assembly. Besides
that, it serve$ as a gating mechanism constituting important part of substrate selectivity and its
association 'll'ith different regulatory protein complexes confers proteasome plasticity (Coux,
Tanaka et al. 1996; Unno, Mizushima et al. 2002). Corresponding to the multiple functions of
subunits,

mo~t

reported post-translational modifications were identified from

According to the structure of 20S proteasome,

a

IX

IX

subunits.

subunits form the inner two-layer of a

four-layer sta¢ked ring structure. This dictates less solvent-exposure-surface compare to
subunits (CoU)(, Tanaka et al. 1996; Unno, Mizushima et al. 2002). Accordingly, less

IX

a subunit

post-translatiqnal modifications were reported. Certain small molecules synthesized by
microorganism!> can form stable adduct with
of the stack. Tfuis is a unique modification to

a subunits of 20S proteasome within the chamber
a

subunit, and these small molecules have been

using as prote*ome inhibitors (Fenteany and Schreiber 1998; Kim, Myung et al. 1999; Kisselev
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and Goldbe~g 2001; Myung, Kim et al. 2001).
The

si~

ATPases forming the base of 19S proteasome are essential for degradation of

poly-ubiquiti/1ated proteins. They open the gate constituted by

IX

subunits, unfold and transfer

protein substrates to the proteolytic chamber. Mutational study has shown that Rpt2 is an essential
part for degr~dation of poly-ubiquitinated proteins (Coux, Tanaka et al. 1996; Bochtler, Ditzel et al.
1999; Glickman and Ciechanover 2002). Post-translational modifications on ATPases serve as
control mecHanisms for their function (Mason, Murray et al. 1998; Zhang, Su et al. 2003).
Rpn10 i$ a poly-ubiquitin receptor, and Rpn11 is a de-ubiquitinase (UCH family). Functions of
other components of 19S proteasome are less defined. Studying the post-translational control of
these compohents would help characterize their functions.

Reported Pqst-translational Modifications ofthe 20S and 19S Subunits
Post-tra~slational

removal of N-terminal propeptide from certain 13 subunits ( 13 1, 13 2, 13 5,

13 7) is one df the first reported post-translational modifications. This is an integral part of 20S
proteasome j:lssembly. 131, 13 2 and 13 5 propeptides are removed auto-proteolytically. 13 7
propeptides lis removed by neighboring proteolytic active subunits. Propeptides protect
N-terminal ac.ive sites from acetyl transferase before maturation and have important implication in
the bias of assembly (Zwickl, Kleinz et aJ. 1994; Chen and Hochstrasser 1996;
Seemuller, Lupas et al. 1996; Schmidt, Zantopf et al. 1999; De, Jayarapu et al. 2003).
Phosphorjylation is another modification addressed by multiple manuscripts. Phosphorylated
subunits were! detected in the proteasome, purified from yeast and certain mammalian tissues
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(Bose, Mas~n et al. 1999; Iwafune, Kawasaki et al. 2002). Casein kinase II (CKII) is one of 20S
proteasomel co-purifying enzymes, both in yeast, human erythrocytes and HEK293 (Ludemann,
Lerea et al. ~ 993; Castano, Mahillo et al. 1996; Pardo, Murray et al. 1998). Subunits

IX

3,

IX

7 and

IX

6 are repqrted substrates of CKII. In mutagenesis studies, Ser258, Ser 263 and Ser264 of the

IX

7 subunit lare reportedly phosphorylated in yeast; Ser243 and Ser250 of the

phosphorylaled in rat kidney cell line; and Ser 248 of the

IX

IX

7 subunit are

3 subunit are phosphorylated in yeast

(Castano, Mahillo et al. 1996; Fernandez Murray, Pardo et al. 2002; Iwafune, Kawasaki et al.
2004). The

IX

7 subunit phosphorylation stabilizes the 26S proteasome ((Bose, Brooks et al.

2001). IFN-"y treatment suppresses phosphorylation of 20S proteasome subunits and decreases
26S proteaspme level in the mammalian cell, simultaneously (Bose, Brooks et al. 2001; Rivett,
Bose et al. 2~01; Bose, Stratford et al. 2004). The effect of CKII phosphorylation at the perspective
of 20S prot$asome activity is less addressed. Dr. Arribas group reports that in vitro CKII
phosphorylat,on of rat kidney 20S proteasome does not affect its activity (Castano, Mahillo et al.
1996); while

pr. Passeron suggests CKII phosphorylation has an impact on yeast 20S proteasome

activity (Fer~andez Murray, Pardo et al. 2002). PKA is another 20S proteasome co-purifying
kinases iden1ified both in kidney cell line (HEK293) and bovine pituitary. Radioactive labeling
suggests twol20S proteasome subunits (27kDa and 28kDa respectively) can be phosphorylated
by PKA in vito ((Marambaud, Wilk et al. 1996). Moreover, PKA phosphorylation increases

a5

subunit activi~ of 20S proteasome in vitro (Pereira and Wilk 1990; Marambaud, Wilk et al. 1996).
Polo-like kin~se cO-immuno-precipitates with 20S proteasome. Reportedly, it increases

13

a5

subunit acti~ity of 20S proteasome in both in vitro and in vivo against fluorescent peptide substrate
(Feng, Lon~o et al. 2001). Phosphorylations of 19S proteasome subunits are also reported
(Mason, MUfray et al. 1998; Satoh, Sasajima et al. 2001). However, the phosphorylated sites and
orresponding kinases are to be further investigated. There is no previous publication that
addresses ~ndogenous protein phosphatase as part of 20S proteasome regulation mechanism.
O-linkec;l N-acetylglucosamine modification is a form of glycosylation involved in proteasome
regulation. this modification has been associated with nutritional censoring mechanism. It
negatively a~ects the activity of 26S proteasome, while the impact on 20S proteasome activity was
not significa~t. Rpt2, the critical subunit involved in opening the 20S gate at the bottom, is a
substrate fon this modification (Sumegi, Hunyadi-Gulyas et al. 2003; Zhang, Su et al. 2003;
Zachara andlHart 2004).
HNE is , lipid peroxidation product, which can crosslink proteins. It inhibits 20S proteasome
activity in vit~o. The subunits are not reported (Okada, Wangpoengtrakul et al. 1999). Oxidative
stress can in~uce different modifications upon 20S proteasome, including poly-ADP ribosylation
(Davies and iGoldberg 1987; Grune, Reinheckel et al. 1995; Ullrichk, Reinheckel et al. 1999;
Radak, Sasv~ri et al. 2000). The comprehensive nature and effects of these modifications need to
be further inv~stigated and differentiated.

Regulation

0'

Proteolytic Activities By Post-translational Modifications

As state~ in the above, the regulation of proteasome activity is a collective effect of multiple
post-translatiqnal tags, reflecting the impact of several control mechanisms. From the structural
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and functio~al points of view, three types of regulations can be summarized. PTMs at 19S
supervise repognition and translocation of substrate into the proteolytic active 20S proteasome
chamber. PliMs at 20S proteasomes ex subunits favor certain proteasome activators/repressors,
or affect 13 Isubunit proteolytic activities allosterically. PTMs at 20S proteasomes 13 subunits
regulate 20S1 proteasome activity, allosterically.
20S prqteasome peptidase activities are not always regulated uni-directionally. Inhibitors
specific to qertain 20S proteasome subunit are available commercially, which supports the
possibility of Isubunit specific activity regulation (Kisselev and Goldberg 2001; Myung, Kim et al.
2001; Kissel~v, Garcia-Calvo et al. 2003). Several publications also report that proteasome
activities carl be controlled in a subunit specific manner in certain phYSiological/pathological
settings in Vfvo (Andersson, Sjostrand et al. 1999; Bulteau, Lundberg et al. 2001; Basset,
Raymond et ~1. 2002). Unfortunately, in multiple early publications, only 13 5 subunit activity was
assayed as cj measure of overall 20S proteasome activity, which might be misleading. All three
20S proteasqme subunit specific substrates have to be use to evaluate its overall functionality.

Clinical Implications of Proteasomal Function

Proteasomall Dysfunction Associated with Diseased-Phenotypes
Consistept with the large variety of proteins turned-over by the proteasome, malfunctioning of
this complex pan result in a an ever growing list of diseases. Cancer is among the first and the
most importa~t proteasome malfunction-associated diseases reported. To date, a tremendous
amount of stydies have been conducted into the role of the proteasome in cancer. Bortezomib
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(previously PS-341) from Millennium Pharmaceuticals has been used in cancer therapy (LeBlanc,
Catley et al. ~002; Orlowski, Stinchcombe et al. 2002; Chauhan, Li et al. 2003). The involvement
of Ubiquitin-~roteasome system in cancerous pathogenesis is complicated. Degradation of
pro-apoptoticlprotein, caspases, is controlled by proteasome (Dallaporta, Pablo et al. 2000; Chen,
Smith et al. 2~03). Degradation of p53 and other essentially cell cycle proteins are also manifested
by the protea~ome (Higashitsuji, Higashitsuji et al. 2005; Richardson, Mitsiades et al. 2005).
The invo,vement of the proteasome in neural degenerative diseases is well recognized, such
as Alzheimer'ls disease and Parkinson's disease (Glickman and Ciechanover 2002; Dawson and
Dawson 200~; Ross and Pickart 2004). In fact, parkin is an E3. The Liddle syndrome is the result
of a mutatio~ at kidney ENaC channel protein, which prevents its turnover (Glickman and

•

Ciechanover 12002; Debigare and Price 2003). A mutation at an E3 (E6-AP) occurs in the
Angelman sy~drome. Ubiquitin-proteasome system disorder also affects immuno-response and
muscle wasti~g (Glickman and Ciechanover 2002).
Postulated E~ects of Proteasomes in Ischemic Injury and Protection

Recently" the effect of proteasome inhibition in cardiac protection came to cardiologist's
attention. Dr. Kukan recently published a review article (Kukan 2004); in which it stated ischemia
reperfusion in~uced infarction in brain, heart, kidney and liver can be minimized by application of
proteasome inhibitors. Several research papers also support the view that inhibition of proteasome
is a benefit aQainst cardiac infarction upon ischemia/reperfusion insult (Campbell, Adams et al.
1999; Zhang, iZhang et al. 2001; Luss, Schmitz et al. 2002; Stangl, Gunther et al. 2002; Pye,
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Ardeshirpol/r et al. 2003).
Thoug~

there have been consistent reports of proteasome inhibition leading to protection

against iscHemia, the mechanism remains unknown due to multiplicity of cell types in a target
tissue and iproteasome involves in multiple cell biological pathways. Nevertheless, several
hypotheses nave been proposed.
The fir~t hypothesis is the reduction of immuno-response. In this hypothesis, proteasome
inhibition dotmregulates NF-kB pathway in endothelial cells and lymphatic cells. Consequently,
less Iympha~c cells attach and filtrate though micro-vessels formed by endothelial cells, which
blocks blood Iflow. On the other hand, this downregulation reduces the release cytotoxic cytokines
and inflamm*ory factors. The effect of NF-kB down regulation in cardiomyocyte is unfortunately
not addresse~ (Campbell, Adams et al. 1999; Elliott, Zollner et al. 2003; Pye, Ardeshirpour et al.
2003).
Secondaty up-regulation of heat-shock proteins (HSPs) after proteasome inhibition is another
proposed hy~othesis. Over-expression of HSPs is well recognized to be cardioprotective.
However, in tHis specific setting, whether this upregulation is the primary protective mechanism or
just a side-eff*t, needs further investigation. There is another complicating factor. Several groups
report oxidize~ proteins, due to free radicals produced in ischemialreperfusion injury, are
preferably degraded by 20S proteasome independent of ubiquitination. The increased ability in
preventing pro~ein denaturing by HSPs and the decreased ability in turning-over irreversibly
oxidative dam~ged proteins must be balanced (Kim, Kim et al. 1999; Luss, Schmitz et al. 2002;
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Stangl, Guntrer et al. 2002; Aki, Yoshida et aI.2003).
The

pr~teasome

is involved in the control of apoptosis-related proteins (such as

caspases arid p53). The role of this control in the proteasome inhibited cardioprotective model
need to be studied (Dallaporta, Pablo et al. 2000; Chen, Smith et al. 2003; Higashitsuji,
Higashitsuji $t al. 2005; Richardson, Mitsiades et al. 2005). There are more hypotheses that can
be formed,

~aking

this model even more complicated.

In short proteasome-inhibition-induced cardio-protection involves the interplay between
different cell types and candidate proteins. Simplified models need to be established to
understand tbe molecular details of this process and help design more specific pharmacological
reagents.
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Hypotheses And Aims of This Study
Hypotheses
Withlinformation gained from the yeast proteasomes combined with our current
understan~ing

following

and postulation of the mammalian proteasomes, we have formulated the

t~stable

hypotheses:

Hypothesi. I.
The M,Jrine Cardiac 20S Proteasomes Are A Collection Of Multiprotein Complexes; This
Sub-organeV/e Is Composed Of Essential Subunits And Key Ancillary Associating Partners.

Hypothesi~

II.

The 20$ Proteasomes Hold Multiple Regulatory Sites That Are Essential To The Modulation
of Cardiac ffroteolytic Activity. Posttranslational Modification (e.g .• Phosphorylation) Of The 20S

Subunits Cootributes To This Regulatory Process.

HypotheSiS

m.

The As'f:;ociating Partners of The 20S Proteasomes Facilitate/Assist Isoform-Selective
Modulation

or The Cardiac Proteolytic Activity.
Aims Of This Study

To test t~e above hypotheses, we have organized the following specific aims.

Specific Aim I.!.
Purificatiqn, Isolation, And Proteomic Characterization Of The Murine Cardiac 20S
Proteasomes.

Specific Aim ~1.
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Charactj9rization Of Key Phosphorylation Events Of The 20S Proteasomes; Determination
Whether Sucjh Posttranslational Modifications Play Important Roles In The Modulation of Cardiac
Proteolytic At;tivity.

Specific Ai~ III.
Identific$tion And Characterization Of The Associating Partners of The 20S Proteasomes;
Determination Of Their Roles In The Modulation Of Cardiac Proteolytic Activity.
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CHAPTER II
PURIFICATION OF 20S PROTEASOME FROM MURINE HEART
Introduction

The set~p of a reproducible large-scale purification protocol is the first critical step to
systemically $tudy the structural and the functional characters of murine cardiac 20S proteasome.
Dr. Avram H~rshko, Dr. Aaron Ciechanover from Israel and Dr. Irwin Rose from United States of
America pionleered the studies in ubiquitin-proteasome degradation pathway. As recognition of
their contribtlJtions, they shared the Nobel Prize in Chemistry 2004. The highlight of their
contribution i$ elucidation the mechanism of the selective ubiquitination and discovery of E1, E2,
and E3 in th~ 80s, which brought controlled protein degradation to the focus of the biological
community. 110 date, the proteasome is found in all three kingdoms of organisms: archbacteria,
eubacteria a~d eukaryotes (Coux, Tanaka et al. 1996; Bochtler, Ditzel et al. 1999; Glickman and
Ciechanover ?002). The primary sequence and quaternary structure of the 20S proteasome show
great conserv~tion across species. Several purification strategies have been proposed. Based on
the nature of the methods, they can be classified into three groups: classic biochemical purification
protocols (re~rred to as the classical method from now on), immunoprecipitation protocols
(referred to a$ the immunoprecipitation method from now on) and affinity purification protocols
(referred to a~ the affinity method from now on) (Glickman and Ciechanover 2002; Leggett,
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In the classical protocol, we purified the 20S proteasome according to its unique biochemical
properties, iincluding high stability and solubility in high salt solution, high molecular weight and
charge stat~s at certain pH. Sample prepared by the classical method has the advantage of high
reproducibilIty, high purity and the possibility of high yield. The disadvantages include a longer
purification time (3-4 days to finish). Proteins loosely associating with 20S proteasome may be lost
during the Jl>rocedure. The immunoprecipitation (IP) protocol is usually carried out by IP with
proteasomelsubunit-specific antibodies. The IP procedure is less time-consuming and offers the
possibility tq purify a population of endogenous proteasome complexes. However, a simple IP
procedure ccjnnot match a stringent purity requirement. The IgG light chain has a similar molecular
weight as some of the 20S proteasome subunits, which makes mass spectrometric study difficult.
It is also ecpnomically prohibitive to use this method for large-scale purification. The affinity
protocol com~ines the advantages of the two previous approaches. It provides an economical way
for large-scal$, high purity, high reproducibility proteasome purification in short period of time. The
choice of affinity tags is diverse. FLAG, 6X His, protein A have all been proved to be applicable
(Tongaonkar"Chen et al. 2000; Leggett, Hanna et al. 2002; Iwafune, Kawasaki et al. 2004).
However, the need to transfect cells with plasmids that would express the tagged protein limits the
current applic*ions to the cell lines and unicellular organisms (yeast, etc). The choice of protocol
depends on th~ purpose of the study, nature of the sample and the scale of purification needed.
20S protej:lsome has a molecular weight between 600-700kDa, depending on the species. It
is stable in high salt, non-ATP solution. On the other hand, 26S proteasome, with a molecular
weight rangingl from 1300kDa to 2100kDa (19S-20S or 19S-20S-19S), dissociates in such a
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solution intq 208 proteasome and other protein complexes in the presence of high salt (Eytan,
Ganoth et al. 1989; Ugai, Tamura et al. 1993; Fischer, Hilt et al. 1994).

Existing Protocols To Purify Proteasomes From Yeast

Yeast i$ a unicellular eukaryotic organism that can be genetically manipulated easily and
expended in large-scale. All three types of protocols mentioned above are applicable to this
organism.
In term ~f classical purification, there are two representative procedures that are very similar
in nature. Orlle, as described in methods in molecular biology (Leggett, Glickman et al. 2005),
applies yeast cytosolic proteins to two consecutive anion chromatographies followed with gel
filtration chrorjnatography. In the other procedure (Groll, Ditzel et al. 1997), yeast 208 proteasome
are purified tlilrough anion ion-exchange chromatrography, hydroxy-apatite chromatography and
gel filtration chromatography sequentially. The presence of ATP in the purification buffers greatly
affected the eM product obtained. Including ATP in the buffer resulted in both singly capped and
doubly capped 268 proteasome, with the second form usually dominant. When buffers free of ATP
are utilized, the 208 proteasome isolated from yeast was of a purity that the 208 could be
crystallized.
With the power of genetic manipulation, more and more investigators turn to use affinity
resins to bail affinity tagged yeast proteasome (Tongaonkar, Chen et al. 2000; Leggett, Hanna et al.
2002; Iwafune, Kawasaki et al. 2004). This approach Significantly Simplifies purification procedure,
shortens the time needed and lowers the harshness of purification procedure. This preserves
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salt-labile prPteasome subunit or proteasome associating proteins, which would have been lost
during classi~al procedure.

E~isting Protocols To Purify Proteasomes From Mammalian Cell Culture

There alre two sets of protocols for purifying 208 proteasome from mammalian cells, based
on the natur$ of the starting material.
For marlnmalian cell lines, there is no report on large-scale 208 proteasome purification. It
would be time-consuming and cost-prohibitive to pursue such procedure. 'IP and affinity
purifications are the methods of choice. IP is a simpler procedure without the needs of
transformation. However, the introduction of antibody in IP procedure limits the maximal purity we
can reach. 1"he affinity chromatography promises a quicker purification procedure and the
potential of reaching higher purity. On the other hand, the transformation procedure would affect
the status of the cells and affinity-tagged proteasome might have acquired distinct properties
compared to !the endogenous counterparts. For tissue samples, in most cases, the quantity of the
sample to stj:lrt with is not the major concern. On the other hand, genetic manipulation needs
transgenesis j which is a challenging and risky task. To date, the majority of mammalian 208
proteasome $tudies are done with preparations from reticulocyte, liver, and skeletal muscle, due to
their easy av~ilability and accessibility (Rivett 1985; Hough, Pratt et al. 1987; Hoffman, Pratt et al.
1992; Castano, Mahillo et al. 1996; Thomas, Oosthuizen et al. 2002; Hayter, Doherty et al. 2005).
In the classil:;al procedure, 208 proteasome is purified step by step according to its unique
biochemical Rroperties: solubility at high salt concentration (ammonium precipitation), charge state
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(retention tUlle through an anion ion exchange column) and high molecular weight
(ultra-centrifLjgation or gel-filtration chromatography). There are some applications of the IP
procedure, which are small scale and just used to study one or two aspects of 208 proteasome
(8hibatani arid Ward 1995; Feng, Longo et al. 2001).
Significance of Purifying Proteasomes From Cardiac Tissues

The prdteasome has been reported to play important roles in cardiac physiology and
pathology,

e~pecially

in ischemia/reperfusion condition (Campbell, Adams et al. 1999; Bao, 8ato et

al. 2001; Pye, Ardeshirpour et al. 2003; Townsend, Cutress et al. 2004). A comprehensive
understanding of the cardiac 208 proteasome structure, function and regulation is the
pre-requirem~nt

to understand its role in biological context. To gain such knowledge, a highly

reproducible and large-scale purification protocol has to be established.
The mOlilse is an indispensable animal model to study cardiac physiology due to its high
reproduction rate, availability of well-established pathological models, and transgenic lines.
However, the use of mice also imposed challenges. The size of mouse heart is small (around
0.15g for an $ week old mouse heart). Moreover, proteasome expression level in cardiac tissue is
lower than tHat of liver tissue. These arbitrate a criterion to exam the success of purification
protocol: The Iloss of proteasomes during purification has to be minimized to not be cost-prohibitive.
Large-scale murine cardiac 208 proteasome purification protocol has not been reported. Murine
cardiac 208 proteasome purification protocol was able to purify 800119 of >95% pure proteasome
from 12g of dardiac tissue in a single run. This protocol was optimized from a liver purification
protocol (Frenlch, Mayer et al. 2001) to fit the nature of cardiac sample and gain higher purity.

25

Materials and Methods
The Use of Mouse Lines

8 week old male ICR mice from Harlan were used in all studies. Mice were euthanized
according t() NIH and UCLA DLAM guidelines. Heart tissue was taken, washed with TBS to
remove blood and frozen in -80°C freezer until used.

Isolation of Cytosolic Fraction from Whole Heart Lysate

12g of mice heart tissue was homogenized with glass potter homogenizer in homogenize
buffer (20mM Tris-base pH 7.8, 0.1mM EDTA, 1mM Dn, supplemented with protease inhibitor
cocktail from Roche and phosphatase cocktails from Sigma). Homogenate was forced through 4
layers of gauge to remove unbroken connective tissues. Cytosolic fraction was collected as the
supernatant after 2hr centrifugation at 25,000g.

The Use of Protease and Phosphatase Inhibitors

Protease inhibitor cocktail (complete, EDTA free) was acquired from Roche. 1 tablet was used
in 50ml solution. It was essential to minimize the non-specific degradation of proteins by lysosomal
proteases. Importantly, this cocktail does not inhibit 20S proteasome activities.
Phosphatillse inhibitor cocktail 1 (serine, threonine phosphatases inhibitors in DMSO) and
cocktail 2 (acid, alkaline and tyrosine phosphatases inhibitors in aqueous solution) were acquired
from Sigma Aldrich. Both cocktails are supplied as SOX stock. Use of both inhibitors was important
to preserve the endogenous phosphorylation state of intracellular proteins during purification.
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Proteasome Activities Assay and Inhibitors

10111 of 10X proteasome assay buffer (250mM HEPES, pH 7.5; 5mM EOTA; 0.3% SOS) was
aliquotted in each well of a 96-well microplate. 70111 water, 10111 of proteasome sample and 10ul of
10X f1uorphore-linked peptide substrates (500IlM Suc-Leu-Leu-Val-Tyr-AMC, Bachem) were used
sequentially to each well establishing the assay mixture. The incubatation time was set to 1hr after
which the adtivity was measured by fluorometer (Fluoroskan Ascent, Thermo Electron) at an
excitation wavelength of 390nm and an emission wavelength of 460nm.

Fast-Pressure Column Chromatography (FPLC)

All FPLC were conducted using the AKTA Purifier (GE Healthcare, formerly Amersham).
There are two anion ion-exchange chromatography steps during the purification procedure:
preparative s¢ale chromatography and analytical scale chromatography. Same receipt of buffer A
and buffer B were used for both procedures.
Buffer A: Tris 20mM pH 7.4, MgCI2 5mM, OTT 0.5mM, Glycerol 10%;
Buffer B: Tris 20mM pH 7.4, MgCI2 5mM, OTT 0.5mM, Glycerol 10%, KC1600mM.
Preparative chromatography: 200ml Q Sepharose Fast Flow resin (from GE healthcare) was
packed in XK 26/40 column (from Amersham) in-house. Sample was loaded through a 10ml
Superloop. Then its components were resolved with 3-step stepwise salt gradient elution at flow
rate 5ml/min: 45% B, until UV280nm monitor reading goes to baseline; 75% B, collect 200ml;
100% B, until UV280nm monitor goes to baseline.

Analytical chromatography: Pre-packed Mono Q HR 5/50 column was acquired from GE
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healthcare. Sample was loaded through a 2ml sample loop. Then it was resolved with a linear salt
gradient from 0% to 100% B within 17.5 column volume (CV equals 1ml).

50S-PAGE and Western-blotting

SDS PAGE was performed with Bio-Rad Mini-Protean " apparatus according to classic
laemmli protocol using 12.5% poly-acrylamide gels. Electrophoresis was conduced at 120V DC
for 1hr. After that, the gel could either be visualized by Colloidal Coomassie blue G-250 staining
protocol or transferred to nitrocellulose membrane (transblot) for western-blotting. Transfer
efficiency was evaluated by Ponceau S staining.
Western-blotting was proceeded according to standard chemiluminescent procedure: The
transblot was blocked with 5% milk for 1hr; incubated with 1st antibody (1 OOOX dilution in 5% milk,
1% Tween-20) for 1hr; Wash with TTBS (Tris-buffered solution with 1% Tween-20) for 3x5 min;
incubated with HRP-linked 2nd antibody (3000X dilution in 5% milk, 1% Tween-20) for 1hr; Wash
with TTBS for 3x5 min; Finally the transblot was incubated with enhanced chemiluminescence
(ECl) regent ~GE healthcare) for 1min and chemiluminescent signal recorded with film (Kodak).

20 Electrophoresis and Western-blotting

20 electrophoresis was conducted using a Bio-Rad 11cm apparatus. Firstly, purified 20S
proteasome was desalted by TCA/Acetone precipitation. Desalted dry pellet was resuspended
and resolubilized with IPG rehydration buffer (7M urea, 50mM OTT, 4% CHAPS, 0.2% 3-10
Bio-Rad ampholytes). 11cm Nl (non-linear) (BioRad) IPG was rehydrated in the IPG rehydration
solution overnight, and then isoelectrofocusing was conducted with Bio-Rad IEF cell (250V, linear
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gradient 20 min, 250V, step and hold 5hrs, 3000V, linear gradient 1hr, 3000V, step and hold 1hr,
8000V, linear gradient 1hr, 8000V, step and hold for a total of 49375 Vhrs.). After IEF, proteins in
IPG strips were reduced by 2% OTT solution and alkylated by 2.5% 1M sequentially for 10
minutes each. The second dimension electrophoresis was done using Bio-Rad pre-cast Criterion
gel (12.5%). The resulting 20 gel will be either stained with SYPRO RUBY or transferred to
nitrocellulose membrane, which is ready to be used in western blotting.
Western-blotting (WB) was carried out either according to the standard chemiluminescent
procedure (described in II.B.6) or another fluorescent procedure using the Odyssey. Odyssey
fluorescent scanner (Licor) was used to fluorescent WB: Block the transblot with 1% gelatin for 1hr;
Probe with 1st antibody (1000X dilution in 1% gelatin, 0.5% Tween-20) for 1hr; Wash with TTBS
(Tris-buffered solution with 1% Tween-20) for 3x5 min; Probed with Fluorphore-linked 2nd
antibody (3000X dilution in 1% gelatin, 0.5% Tween-20) for 1hr; Wash with TTBS for 3x5 min;
Finally the transblot was scanned. Scanned images were overlaid with SYPRO ruby stain image of
the counterpart.

HPLC Coupled Tandem Mass Spectrometry

Proteins resolved by electrophoresis were digested with trypsin (Promega) and extracted
from the gel. The tryptic peptides were resolved with RP-HPLC column coupled online to a mass
spectrometer, which identified proteins have been digested. Three types of mass spectrometers
have been used in this study: Q-STAR (Applied Biosystems, Q-Tof) , LeQ Oeca XP (Thermo
Electron, lon-trap) and LTQ (Thermo Electron, linear ion-trap). All setups were conducted with LC
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flow rate at 200nl/min and mass spectrometer set at data-dependent-acquisition mode. Spectra
acquired were searched against IPI mouse database using MASCOT search engine (Matrix
Science). Only proteins identified with more than two peptides (peptide score higher than 25 each)
and protein score higher than 80 were reported as positive.

Electron-microscopic Study of Murine Cardiac 20S Proteasome

Carbon~coated

copper grid was positively charged. 1O~I purified murine cardiac 20S

proteasome at 0.15~g/~1 in 20mM Tris-HCI (pH 7.5) was allowed to.bind to the grid for 15min. The
grid was washed with 20mM Tris-HCI (pH 7.5) and then stained with 4% uranic acid (depleted) for
2min. Stained grid was left dry for 15min before ready for electro-microscopic (EM) study. Murine
cardiac 20S proteasome images were recorded with film.

Summary Of the Salient Steps/Reagents That Assured Successful Purifications

Introduction of protease and phosphatase inhibitor cocktails were important to maintain 20S
proteasome in its endogenous state. All purification steps were conducted at 4°C, 10% glycerol
was included in all buffers to minimize denaturation and inactivation of 20S proteasome during
purification. Ultra-centrifugation is used to separate high molecular weight protein complexes from
the rest of the sample instead of using gel-filtration chromatography. This would reduce the loss of
20S proteasome at the expense of longer separation time.
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Results
The Expression of 20S Proteasome In the Murine Heart Versus That In The Liver

20S proteasome has been purified from liver (French. Mayer et al. 2001). The expression
level of the 20S proteasome in the heart and liver showed the 20S proteasome level in the heart is
Significantly less than that of the liver (Figure 1).

Flow-Chart of Murine Heart 20S Proteasome Purification

20S proteasome was reproducibly purified on large-scale from murine cardiac tissue
according to its biochemical properties: high stability and high solubility at high salt concentration
(ammonium sulfate precipitation): unique charging properties at certain pH (anion ion-exchange
chromatography) and high molecular-weight (ultra-centrifugation). The detailed protocol is shown
in a flowchart (Figure 2). This protocol reproducibly gained 20S proteasome with purity higher than
95% from murine heart.

Chromatographic Purification Steps

There were two anion ion-exchange chromatographic steps in the purification procedure.
In preparative scale ion-exchange chromatography. pooled murine cardiac homogenate
cytosolic fraction was resolved through a 200ml column (total volume). 3-step salt concentration
gradient elution resulted in 3 peaks detected with UV280nm monitor. The first peak was the flow
through fraction. which represented contaminant proteins with less negative charges at pH 7.5.
The second peak enriched with murine cardiac 20S proteasome. The last peak enriched with
RNAs and highly negative charged proteins at pH 7.5.

31

In the final analytical chromatography, sample was resolved over a 1ml column with a linear
salt concentration gradient from 0% B to 100% B (OmM KCI to 600mM KCI). 20S proteasome was
recovered in fractions at around 60% B (360mM KCI), which were collected at fraction size of
0.3m!. According to the UV280nm of chromatogram, 20S proteasome is well separated from other
proteins, resulting in purity higher than 95%.

50S-PAGE and Western-Blot Identification of 205 Proteasome Enriched Fractions

Fractions enriched in murine cardiac 20S proteasome peak, suggested by UV280nm
chromatogram, were resolved by SOS-PAGE in duplicate. One replica was stained with
Coomassie blue G-250 to visualize total proteins in the gel (Figure 4, Panel A). It reproduced
characteristic pattern of 20S proteasome, in which multiple bands corresponding to 20S
proteasome subunits were packed between 20kOa and 30kOa. Western-blot over the other replica
using antibodies specific to multiple 20S proteasome a subunits, confirmed the murine cardiac
20S proteasome were enriched in the same fractions (Figure 4, Panel B) as indicated in
Coomassie stain.

The Purified 205 Proteasome is Proteolytically Active

Fractions enriched with murine cardiac 20S proteasome were aliquotted and stored at -80°C.
20S proteasome p5 subunit activity assay was conducted over these fractions. The activity curve
gained (Figure 5) was consistent with UV280nM, Coomassie stain and western-blot. This
documented that these fractions were indeed enriched with murine cardiac 20S proteasomes and
they were catalytically active.
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Electron-microscopic (EM) images of murine cardiac 208 proteasome revealed that they
were intact. The bottom and the side view of the protein complex under EM were consistent with
the theoretical shape gained from X-ray crystallography study (Figure 7).

20 Electrophoresis and LC-MS/MS Characterization of The Molecular Components In The
Murine Cardiac 20S Proteasomes

Murine cardiac 208 proteasome preparation was resolved by 20 electrophoresis and then
stained with SYPRO ruby. All major spots in the 20 gel were sequenced with LC/MS/MS to gain
protein IDs. All 20S proteasome constitutive subunits and one inducible subunit were identified
(Figure 6). The other two inducible subunits were identified in a parallel 10 SOS-PAGE and
LC/MS/MS study (data not shown). Summary of murine cardiac 20S proteasome LC/M8/M8 data
is shown in Table 1.
Theoretical 20 map of murine cardiac 20S proteasome and yeasts 20S proteasome was
generated (Figure 6). Theoretical isoelectric points and molecular weights were obtained using
bioinformatic tools available from the Swiss Institute of Bioinformatics (www.expasy.org).

20 Electrophoresis and Western-blotting Reveals Post-translation Modifications on
Multiple 20S Proteasome Subunits

20

electrophoresis followed

by immunoblotting suggested certain

type of PTMs

(phosphor-theonine, phosphor-serine, phosphor-tyrosine) occurred endogenously at multiple 20S
proteasome subunits (Figure 8, Panel A). Phospho-threonine specific antibody (Santa Cruz)
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recognized a 1, 6 and ~ 3, 7 subunits. Phospho-serine specific antibody (Zymed) recognized a 1,
6, 7 and

~

2, 3, 7 subunits. Phospho-tyrosine specific antibody (Santa Cruz) recognized 1,2,6

subunits, and 3, 7 subunits (Figure 8, Panel A).
Serine phosphorylation of a7 subunits was confirmed with mass spectrometry. The
phosphorylation site was identified to be C-terminal serine-249 residue.

10 Electrophoresis and LC·M5/M5 Analysis Identifies Critical 205 Proteasome Associating

Partners

Comprehensive proteomic study was conducted over purified murine cardiac 20S
proteasome with high throughput LC-MS/MS sequencing. This uncovered casein kinase II (CK2),
cAMP-dependent protein kinase (PKA) and protein phosphatase 2A (PP2A) (Figure 9) as 20S
proteasome associating partners (Table 2).
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Discussion
205 Proteasomes Can Be Purified as An Intact Complex from Murine Heart

20S proteasome is protein complex with unique properties, which can be used to isolate it
from a compl'ex mixture such as tissue homogenate. It has high molecule weight, high stability and
solubility at high salt concentration and high affinity to anion ion-exchange resin at pH 7.5. In a
classical biochemical purification procedure, these unique properties facilitate its purification. In
SDS-PAGE and 2D gel electrophoresis, subunits of purified murine cardiac 20S proteasome
showed the same stoichiometry, which indicated 20S proteasome could be purified from murine
heart intact. On the other hand, Coomassie blue stain showed the absence of 26S proteasome.
Electro-microscopic images gained from further analysis of the purification preparation provided
unquestionable evident that 20S proteasome was intact and 26S proteasome was absent.
The Purified 205 Proteasome is Proteolytically Active

The 20S proteasome has two copies of three catalytic active subunits ([31, [32 and (35) with
distinct peptidase activities (Caspase-Iike activity, trypsin-like activity and chymotrypsin-like activity,
respectively). Recombinant peptides with covalent-linked f1uorophore (Z-Leu-Leu-Glu-AMC,
BZ-Leu-Ser-Thr-Arg-AMC, and Suc-Leu-Leu-Val-Tyr-AMC) were used to assay 20S proteasome
activities (Caspase-Iike activity, trypsin-like activity and chymotrypsin-like activity, respectively).
Besides substrate specificity, there are three more characteristics that distinguish eukaryotic 20S
proteasome from other proteinases/peptidases. It has unique high molecular weight; it is
endogenously in a latent form and this latency can be relieved biochemically with detergent in vitro;
It can be specifically inhibited by inhibitors (epoxomicin and Lactacystin) designed to inhibit
N-terminal hydrolase (Ntn) family proteinase. 20S proteasome purified from murine heart was
shown to be enzymatically active.
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Differential 205 Proteasome Complexes Co-exist in Murine Heart

As shown from the LC-MS/MS sequencing study, both constitutive and inducible 20S
proteasome subunits existed in the murine cardiac purification preparation. Moreover, SYPRO
Ruby staining and Western blot of murine cardiac 20S proteasome resolved with 20 gel indicated
the presence of endogenous PTMs on 20S proteasome subunits. This gave a sense on the
complexity of 20S proteasome population in murine heart, which suggested this mega-protease is
under the joint control of multiple mechanisms. Despite a variety of PTMs, phosphorylation is the
most interesting due to its ubiquitous and dynamic nature. A comprehensive proteomic study
combining the power of western blot with specific antibodies and mass spectrometry, showed that
phosphorylation is an important regulator of the 20S proteasome activity endogenously.

205 Proteasome Associating Partners May Play Regulatory Roles

Elucidated by the purification flow chart (Figure 2), the whole purification is a three-day
procedure including one salt precipitation, one dialysis, one ultra-centrifugation and two
ion-exchange chromatography steps. The purity of 20S proteasome in the final preparation is
higher than 95%. In this stringent condition, only proteins that associate with 20S proteasome
fairly strong would have remain in the final preparation. In fact, the well-known 20S proteasome
stoichiometric associating partner, the 19S, cannot survive this procedure. 20S proteasome
associating proteins consistently identified form the purification preparation should have significant
impact on 20S proteasome functions. Indeed, several proteins have been consistently identified in
the purification preparation and correspond to previous reports. Among them, PKA, CK2 and
PP2A are kinases or phosphatase that regulate protein phosphorylation status and possibly
responsible for endogenous 20S proteasome phosphorylation control.
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Summary

Large scale 208 proteasome purification from murine heart was established according to
classic biochemical protocol. There were optimizations within the chromatography steps and
ultra-centrifugation step. Murine cardiac tissues were more precious than rat liver tissue and 208
proteasome expression level was lower in the heart than that of the liver, these optimizations have
been proved to be important. In the final chromatography step, 208 proteasome was recovered as
a single peak without overlapping with others. The purity of the preparation was further evaluated
by multiple methods. 8taining of purified murine cardiac 208 proteasome resolved with 808 PAGE
or 20 electrophoresis documented the purity higher than 95%. Electronic-microscopy image
showed the shape of 208 proteasome in the preparation was consistent with that documented in
X-ray study, which served as a measure of the integrity of 208 proteasome in the preparation.
Proteasome activity assay proved its activity had been preserved during the preparation
procedure.
In a proteomic study of purified murine cardiac 208 proteasome, the complexity of this
seemingly simple protein complex emerged. Besides all 14 constitutive expressing subunits,
inducible subunit PSi was also identified within the 20 gel. The other two inducible subunits, P1i
and P2i, were identified by mass spectrometer, after resolving purified murine cardiac 208
proteasome with 808 PAGE. In addition, several 208 proteasome subunits were each
represented by multiple spots in the 20 gel, which was a clear indication of the existence of PTMs.
Consistent to this notion, the pi of purified murine cardiac 208 proteasome was 5.2, which is 0.8
unit lower than the value predicted with bioinformatic tools for un-modified 208 proteasome. In a
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subsequent western blot study, these PTMs appear to at least include serine-phosphorylation,
threonine phosphorylation and tyrosine phosphorylation. a7 subunit was identified to be
phosphorylated at serine-249 by mass spectrometry.
Several enzymes, regulating 20S proteasome phosphorylation status, have been identified
with purified cardiac 20S proteasome preparation, namely, PKA, CK2 and PP2A. PKA and CK2
have been identified in other tissue as 20S proteasome associating proteins, while PP2A has been
suggested as potential 20S proteasome associating protein by a yeast-2-hybrid experiment. The
functional impacts of these enzymes on 20S proteasome are discussed in detail in the following
section.
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Figure 1. The Expression of 205 Proteasome In the Murine Heart and Liver. Murine heart and
liver cytosolic proteins were resolved by SDS-PAGE. Western blot was conducted using antibody

that recognize multiple 205 proteasome a subunits (Biomol). 205 proteasome expression level in
the heart is much lower than that of liver (absorption density analysis showed heart 20S
proteasome expression level is 1/3 of that of liver).
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Figure 2. Flow-Chart of Murine Heart 20S Proteasome Purification. Murine cardiac 20S
proteasome purification is a classical biochemistry purification procedure, which purify the 20S
proteasome according to its biochemical property.
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Collect Cytosolic Fraction from Heart Tissue Homogenate by Centrifugation

Ammonium Sulfate Precipitation (Coliect 40-60% Pellet)

Q Fast Flow lon-exchange Chromatography (3 Steps Elution)

Ultra-centrifugation (200,000g, 19 hrs at 4 °C), Collect Pellet

Mono Q lon-exchange Chromatography, Murine Cardiac 20S Proteasome (95% pure)
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Figure 3. Chromatographic Purification Steps. Panel A. Preparative scale Q 8epharose Fast
Flow anion ion exchange chromatogram. 3 steps salt concentration was used. 45% B (270mM KCI)
to let majority of contaminant protein flow through the column without binding; 75%

B (45mM KCI)

to elute semi-pure 208 proteasome from the column; 100% B (600mM KC!) to remove RNA bound
to the column. Panel B. Analytical scale Mono Q HR 5/50 anion ion exchange chromatogram.
Linear salt concentration gradient was used to resolve proteins in the sample. All the peaks (UV
280nm) were well separated and 208 proteasome was represented with the highest absorbance.
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Figure 4. 50S-PAGE and Western-Blot Identification of 205 Proteasome Enriched Fractions.
Panel A. Fractions collected by analytical Mono Q FPLC were resolved by SOS-PAGE and then
stained with coomassie blue. 20S proteasome subunits have unique pattern in SOS-PAGE, in
which multiple bands clustered between 20KOa and 30KOa. The proteasome-enriched fraction
shown in SOS-PAGE Coomassie stain was consistent with UV280 chromatogram. Panel B. Same
fractions collected by analytical Mono Q FPLC were resolved by SOS-PAGE and transferred to
nitrocellulose membrane. Western blot was conducted with antibody recognizing multiple 20S
proteasome a subunits (a1, 2, 3, 5, 6, 7). The proteasome-enriched fraction shown in western blot
was consistent with both UV280 chromatogram and Coomassie blue staining pattern.
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D12

E1

E2

E2

Figure 5. The Purified 205 Proteasome is Proteolytically Active. 208 proteasome
activity

was

measured

with

fractions

collected

by

analytical

Mono

Q

pS subunit

FPLC.

The

proteasome-enriched fraction shown in the assay was consistent with UV280 chromatogram,
Coomassie stain and western blot. This suggested that purified 208 proteasome from murine
heart are catalytically active.
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Figure 6. 20

Electrophoresis and

LC-MS/MS

Characterization of The

Molecular

Components In The Murine Cardiac 20S Proteasomes. Panel A. Theoretical 20 map of murine
20S proteasome. Isoelectric point and molecular weight of 20S proteasome subunits were
predicted with bioinformatic tool (www.expasy.org). Panel B. SYPRO Ruby stain of murine cardiac
20S proteasome resolved by 20 Electrophoresis. Spots from the 20 gel were picked and identified
with mass spectrometer. Several 20S proteasome subunits were represented by multiple spots in
the 20 gel, which is a clearly indication of post-translational modification. Panel C. Theoretical 20
map of murine 20S proteasome. Isoelectric point and molecular weight of 20S proteasome
subunits were predicted with bioinformatic tool (www.expasy.org).
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Murine

+-eo
MW (kDa)

Yeast
+-20

Table 1. Murine cardiac 20S proteasome subunits Identified by LC/MS/MS. All 208
proteasome subunits were identified from murine heart, including constitutive subunits and
inducible subunits. Theoretical pI of murine 208 proteasome is 6.0 (www.expasy.org), however,
the experimental pI of murine cardiac 208 proteasome was 5.2. This indicated that 208
proteasome is post-translational modified in murine heart.
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Gene
Names

Common
Names

#
a.a

Theoretical
MW

Estimated
20E MW

Sequence
Coverage

208 Proteasome PI

Theoretical:
6.0
Experimental:
5.2
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Figure 7. Electro-microscopic Analysis of Murine Cardiac 20S Proteasome. Murine cardiac

20S proteasome was imaged with Electro-microscopy after negative staining with uranic acid. The
images were taken at 100,OOOX magnitude.

•
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Electro-microscopic Image of 20S Proteasome (100,000X)

... Rnllnm Vip.w --.

... Side View
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--.

Figure 8. 20 Electrophoresis and Western-blotting Reveals Post-translation Modifications
on Multiple 20S Proteasome Subunits. 25ug of purified Murine cardiac 20S proteasome each

was resolved by 20 electrophoresis (Bio-Rad), a total of 4 gels were run in parallel. Three of which
was then transferred onto nitrocellulose membrane and immunoblotled with antibodies
recognizing the phospho-Threonine, phospho-Serine, or phospho-Tyrosine proteins. Signal to
noise ratio was set to be 2.5 folds highe,...than that of the background. The fourth 20 gel was
stained with Sypro Ruby. The signals of phospho-proteasome subunits were identified by
comparing/overlaying the 20 image of Sypro Ruby with that of the phospho-antibody gel.
PanelA.

Upper membrane: Monoclonal antibody against phospho-threonine was purchased from Santa
Cruz, which recognized subunits (alpha 1, 6 and beta 3,7)
Middle membrane: Polyclonal antibody against phospho-ser was purchased from Zymed, which
recognized subunits (alpha 1,6,7 and beta 2,3,7). Although alpha7 signal was below our pre-set
threshold, it has been confirmed with LC/MS/MS:
Lower membrane: Monoclonal antibody against phospho-tyr was purchased from Santa Cruz,
which recognized a 1,2,6 subunits, and b 3, 7 subunits.
Panel B. Endogenous phosphorylation site of 20S proteasome ex 7 subunit was identified with

mass spectrometry to be Serine 249 residue at the C-terminal.
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Figure 9. Protein Phosphatase 2A (PP2A) Associates with Murine Cardiac 205 Proteasome.
Purified murine cardiac 20S proteasome were resolve in SDS-PAGE in duplicate. Panel A.
LC-MS/MS analysis of proteins resolved in one replica identified all three subunits of PP2A. The
mascot report for subunit A was shown. Panel B. Western blot analysis of the other replica
confirmed the presence of PP2A subunit C.
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PanelA.
Match to: IPIOO310091 Score: 1330
Tax.Jd=10090 EnsembUocations(Chr-bp):17-19454629 Protein phosphatase 2, Subunit A
Nominal mass (Mr): 66119; Calculated pi value: 5.00

NCBI BLAST search of

against nr

Fixed modifications: Carbamidomethyl (C)
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mod~ications:

N-Acetyl (Protein),Oxidation (M), Pyro-glu (N·term E),Pyro-glu (N-term Q)

Cleavage by Trypsin: cuts C-tenn side of KR unless next residue is P
Sequence Coverage: 45%
Matched peptides shown in Bold Red

1 MAAADGDDSL YPiAVLIDEL RNEDVQLRLN SIKKLSTIAL ALGVBRTRSE
51 LLPFLTDTIY DEDEVLLALA EQLGTFTTLV GGPEYVHCLL PPLESLATVE
101 ETVVRDKAVE SLRAISHEHS PSDLBAHFVP LVKRLAGGDW FTSRTSACGL
151 PSVCYPRVSS AVKAELRQYP RNLCSDDTPM VRRAAASKLG EFAXVLELDN

201
251
301
351

VKSEIIPMFS
AAEDKSWRVR
AASHKVKEFC
GLSPILGKDN

NLASDBQDSV
YMVADKPTEL
ENLSADCREN
TIEHLXPLFL

RLLAVEACVN
QKAVGPEITK
VIMTQILPCI
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IAQLLPQEDL
TDLVPAFONL
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RLNIISNLDC

EALVMPTLRQ
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VKSALASVIM
VNEVIGIRQL
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451
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551

SQSLLPArvE
LVDHVYAIRE
TLFCINVLSE
LDNSTLQSEV

LAEDAKWRVR
AATSNLKKLV
VCGQDITTKH
KPILEKLTQD

LAIIEYMPLL
EKFGKEWAHA
MLPTVLRMAG
QDVDVKYFAQ

AGQLGVEFFD EKLNSLCMAW
TIIPKVLAMS GDPNYLHRMT
DPVANVRFNV AKSLQKIGPI
BALTVLSLA

Panel B.

Purified

208 proteasome

Positive control: total heart lysate

PP2A Subunit C ---.
36kDa

2U9

2U9
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20U9

70U9

Table 2. 10 Electrophoresis and LC·MS/MS Analysis Identifies Critical 20S Proteasome
Associating Partners.
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CHAPTER III

PHOSPHORYLATION AS A KEY REGULATORY MECHANISM OF
THE CARDIAC 20S PROTEASOME

Introduction

The 20S proteasome is a stable protein complex with long half-life. On the other hand, the
20S proteasome assembly process is also prolonged for an enzyme. The dynamic regulation of
20S proteasome activities has to be achieved post-translation ally for rapid responses, especially
under stress conditions. Several forms of post-translational modifications (PTMs) occur on the
proteasome. They could occur Simultaneously or alternatively, including replacement of
constitutive 20S proteasome subunits with inducible counterparts; selective association with
activating/inhibiting protein complexes; and covalent PTMs (Coux, Tanaka et al. 1996; Rivett,
Mason et al. 1997; Baumeister, Walz et al. 1998; Bochtler, Ditzel et al. 1999; Glickman and
Ciechanover 2002).
Phosphorylation is the covalent post-translation addition of a phosphate group that has been
drawing the most attention from biologists. The ubiquity of this modification and instant, reversible
nature of this modification, justify this bias. Protein kinases transfer the y-phosphate group of an
ATP to certain amino acid residues of a protein substrate. Such modification mostly occurs at
serine, threonine and tyrosine residues. Phosphorylations on histidine and aspartate residues also
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occur, but are rare. Hundreds of kinases have been identified so far. They have great sequence
diversity, but all share two homogenous domains for ATP binding and catalyzing phosphate group
transfer, respectively. The remaining part of the kinase sequence dictates its binding affinity with
other proteins and substrate preference. Consequently, a kinase can only phosphorylate the
consensus sequence in certain substrates. The chemical property of hydroxyl groups is similar
between serine and threonine residues, which are distinct from that of tyrosine. Accordingly,
kinases are catalogued into two families: serine/theonine kinases preferably phosphorylate serine
and threonine residues and tyrosine kinases preferably phosphorylate tyrosine residues of a
protein. The specificity of the kinase enables it to play an important role in certain signaling
cascades. Protein phosphatases are a group of enzymes that counteract the function of kinases
by removing a phosphate group from phosphorylated-protein substrates. Serine/threonine
phosphatases, tyrosine phosphatases, alkaline phosphatases and acid phosphatases constitute
four families of phosphatases. Compared to kinases; the substrate bias is much lower for
phosphatases. Correspondingly, there are fewer protein phosphatases than kinases within the
cells. The phosphorylation status of a protein affects its enzymatic activity, subcellular localization,
and half-life. Kinases and phosphatases coordinately control intracellular phosphorylation
signaling cascades, which is important for the cell to maintain homeostasis and response to
environmental changes (Johnson and Lewis 2001).
Phosphorylations have been identified in the 20S proteasome purified from both yeast and a
few mammalian tissues, such as kidney, liver, etc. The phosphorylation profile of the 20S
proteasome from the murine heart is lacking (Pereira and Wilk 1990; Castano, Mahillo et al. 1996;
Bose, Mason et al. 1999; Feng, Longo et al. 2001; Fernandez Murray, Pardo et al. 2002; Iwafune,
Kawasaki et al. 2002; Bose, Stratford et al. 2004).
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According to the stUdies described in

previously section, the 208 proteasome was endogenously phosphorylated in the murine heart.
The study presented in this chapter further confirmed the murine cardiac 208 proteasome was
phosphorylated. Moreover, attempts have been made to put these phosphorylations into a
biological context.
In certain mammalian tissues, casein kinase II (Ck2), PKA and polo-like kinases have been
reported as 208 proteasome associating kinases, which could directly control the 208 proteasome
phosphorylation state (Pereira and Wilk 1990; Castano, Mahillo et al. 1996; Marambaud, Wilk et al.
1996; Feng, Longo et al. 2001). However, there is no such study for mammalian cardiac tissue.
PKA and polo-like kinases have been reported capable of increasing 208 proteasome

p5 subunits

activity. The effect of CK2 phosphorylation on the 208 proteasome function has been contradicting
in different reports. In part II of this thesis, CK2 and PKA have been identified as 208 proteasome
associating kinases in murine heart, which is consistent with other tissues. Protein phosphatase
2A (PP2A) has been identified as the 208 proteasome associating phosphatase in murine heart. A
yeast-two-hybrid study suggested PP2A might interact with 208 proteasome. There is no previous
proteomic study reported PP2A interacting with 208 proteasome in mammalian tissues. A
comprehensive 208 proteasome functional study is needed to uncover how murine cardiac 208
proteasome are regulated functionally by these kinases/phosphatase.

63

Materials and Methods
Purified Murine Heart 20S Proteasome
10g of mice heart tissue was homogenized by a potter homogenizer in homogenize buffer
(Tris 20mM pH 7.8, EOTA 0.1 mM, OTT 1mM, with protease inhibitor cocktail from Roche and
phosphatase cocktails from Sigma). Cytosolic fraction was collected as the supernatant after 2hr
centrifugation at 25,000g. Cytosolic fraction was then fractionated by ammonium sulfate
precipitation. The pellet collected between 40% to 60% ammonium sulfate saturation was
re-suspended in 10ml dialysis buffer (Tris 20mM pH 7.4, MgCI2 5mM,

on

0.5mM). The

re-suspended fraction was dialyzed again with 4L dialysis buffer overnight, to remove ammonium
sulfate from it. The dialysate was fractioned with preparative-scale strong-anion-ion-exchange
column (Q FastFlow resin packed in XK 26/40 column from GE healthcare) by stepwise salt
concentration gradient elution at flow rate 5mllmin (45% B, until UV280nm monitor reading goes to
baseline; 75% B, collect 200ml; 100% B, until UV280nm monitor goes to baseline. Buffer A: Tris
20mM pH 7.4, MgCI2 5mM,

on 0.5mM,

on 0.5mM, Glycerol 10%; Buffer B: Tris 20mM pH 7.4, MgCI2 5mM,

Glycerol 10%, KCI 600mM). 75% B fraction enriched in 20S proteasome. This

fraction was centrifuged at 5°C 42,OOOrpm (Ti45 fixed angel rotor from Beckman) for 19hr. The
pellet

was

collected,

re-suspended

in

buffer

A

and

resolved

with

analytical-scale

strong-ion-exchange column (Mono Q HR5150 from GE healthcare) with a linear salt concentration
gradient from 0% B to 100% B through 17.5 column volume. The purified 20S proteasome was
recovered in fractions around 60%B.
Calf Intestinal Alkaline Phosphatase
Calf Intestinal Alkaline Phosphatase (ClAP) was purchased from Promega; Agarose
crosslinked ClAP was purchased from Sigma. 10X ClAP assay buffer (0.5M Tris-HCI pH 8.5,
10mM MgCI2 , 1mM ZnCI 2 ) was prepared using reagents obtained from Sigma.
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Phosphatase Inhibitors
The protein phosphatase 2A specific inhibitor, okadaic acid, was purchased from Calbiochem.
Okadaic aci¢l does not affect tyrosine phosphatase, acid phosphatase and alkaline phosphatase.
Its specificity towards protein phosphatase 2A is 100 folds higher than that towards protein
phosphatase 1 (PP1).

Kinase Inhibitors
PKA specific inhibitor, H-89, was purchased from Calbiochem.
CK2 specific inhibitor, 4,5,6,7-Tetrabromobenzotriazole, was purchased from Calbiochem.

ClAP Treatment of 20S Proteasome
ClAP treatment of 205 proteasome: To different wells of a 96-well microplate, 0.0651lg
purified murine cardiac 205 proteasome incubated with ClAP at 37°C. Then 10X 205 proteasome
assay buffer and 10X 205 proteasome substrate stock were added immediately or after 30min
incubation. After 1hr incubation at 37°C, the proteasome activity was measured using
fluorescently labeled substrates.
CIAP-agarose treatment of 205 proteasome: To each micro-centrifuge tube, 0.0651lg purified
murine cardiac 205 proteasome incubated with ClAP at 37°C for 30min. CIAP-agarose was
removed by centrifugation; supernatant was transferred to 96-well microplate. Then 10X 205
proteasome assay buffer and 10X 205 proteasome substrate stock were added. After 1hr
incubation at 37°C, proteasome activity was measured using fluorescently labeled substrates.

Phosphorylation of 20S Proteasome
205 proteasome was incubated with PKA (5igma) in assay buffer (50mM Tris-HCI, pH 7.5,
20mM MgCI2, 1mM Dn, 2mM ATP) at 35°C for 15min. Then the reaction mixture was dispensed
into 96-well microplate, complemented with 10X assay buffer and 10X substrate stock. After 1hr
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incubation at 37°C, the proteasome activity was measured using f1uorescently labeled substrates.
20S pnoteasome was incubated with casein kinase II (New England Biolabs) in assay buffer
(SOmM Tris-HCI, pH 7.S, 20mM MgCI2, 1mM

on, 2mM ATP) at 3SoC for 1Smin. Then the reaction

mixture was dispensed into 96-well microplate, added with 10X assay buffer and 10X substrate
stock. After 1hr incubate at 37°C, proteasome activity was measured using f1uorescently labeled
substrates.

Fluorescent Peptide Substrates and 20S Proteasome Activities Assay
Z-Leu-Leu-Glu-AMC from Sigma was used to measure 131 subunit activity. (10X assay buffer:
2S0mM HEPES, pH 7.S; SmM EOTA; O.S% NP-40; 0.01 % SOS). Boc-Leu-Ser-Thr-Arg-AMC from
Sigma was used to measure 132 subunit activity. (10X ssay buffer: 2S0mM HEPES, pH 7.S; SmM
EOTA; O.S% NP-40; 0.01% SDS). Suc-Leu-Leu-Val-Tyr-AMC from Bachem was used to measure
13S subunit activity. (1 OX assay buffer: 2S0mM HEPES, pH 7.S; SmM EDTA; 0.3% SDS).
Different concentrations of substrate (0, 2, 10, 20, SO, 100, 200, SOOIlM) were used in 20S
proteasome activity assays to generate substrate concentration dependent activity curves.

SDS-PAGE and Phosphor-protein Detection by Pro-Q Staining
Purified murine cardiac 20S proteasome incubated with CIAP-agarose or albumin-agarose
resin at 37°C for 30min. Then the beads were removed by centrifugation. Supernatant were
collected and resolved by SDS-PAGE. The proteins in the gel was fixed and stained with
phospho-protein specific dye according to standard protocol from the vendor (Pro Q Diamond from
Molecular Probes).

Statistical Analysis
All data are presented as Mean±S.E. Groups are compared using the student's t test for
unpaired data. A P value of less than O.OS was considered significant.
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Results
ClAP Treatment Removes Phosphate Groups from Phosphorylated 20S Proteasome

Purified murine cardiac 20S proteasome were treated with ClAP (buffer only treatment serves
as negative control). Then the 20S proteasome was resolved with SDS-PAGE and stained with a
phosphor-protein specific dye (Pro-Q Diamond from Molecular Probes) and total protein stain
(SYPRO Ruby from Molecular Probes) sequentially. The fluorescent signal of SYPRO Ruby stain
showed no intensity differences between the treated and negative control (Figure 10, Panel 8).
However, between the same two groups, Pro-Q Diamond staining resulted in distinct fluorescent
signals (Figure10, Panel A). The murine cardiac 208 proteasome was phosphorylated
endogenously and these phosphate groups could be removed by ClAP treatment.

ClAP Treatment Selectively Increases 20S Proteasome Peptidase Activities

ClAP treatment also regulates 20S proteasome peptidase activities. Two ClAP treatment
protocols were used. According to the first protocol, 20S proteasome and ClAP were added to the
microplate simultaneously with 20S proteasome assay buffer and 20S proteasome substrate,
which was set as time O. Fluorescent signals from cleaved substrates were recorded in an hour at
37°C to measure peptidase activities. The result showed ~1 subunit activity did not change
significantly. P2 subunit activity increased significantly, while ~5 subunit activity was slightly
inhibited (Figure 11, Panel A).
According to the second protocol, the 20S proteasome was pre-treated with ClAP for 30min
at 37°C. At time 0, proteasome assay buffer and substrate were added to evaluate proteasome

67

activities within an hour at 37°C. In this setup,

~1

subunit activity remained unchanged.

activity was enhanced dramatically. Notably, the

~5

~2

subunit

subunit activity was upregulated in this

condition (Figure 11, Panel B).

Removal of ClAP from the De-phosphorylated 205 Proteasome
Increases the Peptidase Activities Greater than When ClAP is Present

Agarose-crosslinked ClAP was obtained from Sigma. This form of ClAP could be removed
after treatment with a simple centrifugation procedure. This enabled us to isolate the 20S
proteasome from the ClAP.
Purified murine cardiac 20S proteasome was pre-treated with CIAP-agarose beads for 30min
at 37°C. At time 0, CIAP-agarose beads were removed; proteasome assay buffer and substrate
were added to evaluate proteasome activities within an hour at 37°C.
no significant difference.
condition,

~5

~2

~1

subunit activity showed

subunit activity was enhanced significantly. Importantly, in this

subunit activity was enhanced the most significantly (Figure 12, Panel A).

In another assay, purified murine cardiac 20S proteasome was pre-treated with
CIAP-agarose for 30min at 37°C. At time 0, CIAP-agarose beads were removed; proteasome
assay buffer and substrate were added along with recombinant ClAP. After 1hr incubation at 3]oC,
20S proteasome activities were measured via recording fluorescent emission.
no significant difference.

~2

~1

subunits showed

subunit activity was induced significantly. Importantly,

~5

subunit

activity was enhanced less significantly than previous setup, which mimicked the results of
recombinant ClAP pre-incubation (Figure 12, Panel 8).
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Casein Kinase II Co-purifies with 205 Proteasome

Purified murine cardiac 20S proteasome were pre-incubated with various amount of CKII
(Trace amount of CKII had been showed to co-purify with murine cardiac 20S proteasome) at
35°C for 15min in phosphorylation buffer (50mM Tris-HCI, pH 7.5, 20mM MgCI2, 1mM

on, 2mM

ATP). At time 0, proteasome assay buffer and substrate were added to evaluate proteasome
activities within an hour at 3rC. Data showed all three proteasome peptidase activities were
enhanced by this treatment (Figure 13).

Phosphorylation of 205 Proteasome Changes 205 Proteasome Activities

Purified murine cardiac 20S proteasome were pre-incubated with various amount of PKA
(Trace amount of PKA had been showed to co-purify with murine cardiac 20S proteasome) at
35°C for 15min in phosphorylation buffer (50mM Tris-HCI, pH 7.5, 20mM MgCI2, 1mM

on, 2mM

ATP). At time 0, the proteasome assay buffer and substrate were added to evaluate proteasome
activities within an hour at 3rC. Data showed all three proteasome peptidase activities were also
enhanced by this treatment (Figure 14).

Protein Phosphatase 2A Co-purifies with 205 Proteasome, Which may Regulate 205
Proteasome Activities by Removing Phosphate Groups from the 205 Proteasome in vivo

Purified murine cardiac 20S proteasome were pre-incubated with various amount of PP2A
inhibitor, okadaic acid (PP2A had been showed to co-purify with murine cardiac 20S proteasome)
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at 35°C for 30min. At time 0, proteasome assay buffer and substrate were added to evaluate
proteasome activities within an hour at 37°C. Treatment of purified murine cardiac 20S

proteasome with PP2A inhibitor significantly increased all

~

subunit activities, especially ~1 and

~5

(Figure 15, Panel A).
Purified murine cardiac 20S proteasome were pre-incubated with various amount of PP2A at
35°C for 15min. At time 0, proteasome assay buffer and substrate were added to evaluate
proteasome activities within an hour at 37°C. Treatment of purified murine cardiac 20S
proteasome with PP2A significantly decreased

~1
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and

~5

subunit activities (Figure 15, Panel B).

Discussion
205 Proteasome is Phosphorylated in vivo

20S proteasome has been shown to be phosphorylated endogenously in yeast, rice and
several mammalian tissues. Several subunits are phosphorylated in a similar fashion in all these
samples, while there are also subunits showing clear distinction on phosphorylation status among
samples.
As described in detail in part II, the murine cardiac 20S proteasome was purified and western
blotting with phosphor-protein specific antibodies and mass spectrometric showed that this cardiac
20S proteasome was phosphorylated endogenously. In a ClAP de-phosphorylation/Pro-Q
phosphor-protein stain study; this was further confirmed. Phosphorylation is one of the important
mechanisms to regulate 20S proteasome in murine heart.
The Choice of Detergents has an Effect on 205 Proteasome Activities Assay

The 20S proteasome is a latent protein complex with peptidase activities. The two
seven-subunits ex rings impose this latency. In latent state, N-terminal sequences of ex subunits
block the entrance for substrates to reach the catalytic core. In vivo, this latency can be relieved by
activator protein complexes, including 19S regulatory particles, 11S and PA200, which can open
the entrance by inducing conformation changes of these N-terminal sequences. In vitro, this
activation can be mimicked with detergents, which can also induce conformational changes. Out
of the various choices of detergents, SOS is most commonly used, even though, there are reports
that show that SDS is not optimal for all subunit activity assays. The popularity of SDS has both a
historical reason and an economical reason. During the early days of proteasome activity studies,
the

pS

subunit activity assay was used as single criteria to evaluate the function of this protein
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complex, and 8D8 was optimal for this assay. As more and more researchers realize the needs of
comprehensive evaluation of 208 proteasome activities by measuring all three 208 proteasome
peptidase activities, it required the establishment of optimal assay protocols for each peptidase
activity assay. NP-40 is another detergent that has been used in proteasome activity assay. The
efficiency of 808 and NP-40 in inducing the 208 proteasome peptidase activities was compared.
Data showed NP-40 was a better detergent for P1 and P2 subunit activity assays, while 808 was
the better detergent for the

pS subunit activity assay.

ClAP Treatment Removes the Phosphorylation-dependent Inhibition of 205 Proteasome

ClAP treatment removed serine, threonine phosphorylation and tyrosine phosphorylation. As
to its name, Calf Intestinal Alkaline phosphatase has optimal enzymatic activity at alkaline pH,
which is 9.3. However, 208 proteasome is less stable beyond pH 8.5. Excess molar amount of
ClAP has to be used to de-phosphorylate 208 proteasome completely. Pro-Q diamond is a
fluorescent dye that selectively recognizes phospho-proteins. Pro-Q diamond staining showed
ClAP treatment could efficiently remove phosphate groups from 208 proteasome.
Comparing 208 proteasome activities with or without ClAP complete de-phosphorylation, it
showed phosphate conjugation having Significant functional significance. P1 subunit activity was
not altered by complete de-phosphorylation with ClAP. The P2 activity was significantly enhanced
while the effect on the

pS

subunit activity was relative complicated. The

pS

activity was slightly

decreased if activity assay was conducted simultaneously with ClAP treatment, while its activity
was significantly increased if proteasome activity assay was conducted after 30min ClAP
pre-treatment. This raised the possibility that ClAP can be degraded by 208 proteasome. As a
substrate, ClAP competes proteolytic active sites with peptide substrates, which would decrease
208 proteasome activity measured with peptide substrates. In an inhibition study, the
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pS subunit

was reported as the main subunit responsible for protein degradation. Its inhibition resulted in 50%
less in protein degradation rate. Several proteins have been reported to be degradated by 20S
proteasome independent of ubiquitin. This could be the explanation for distinct effects with
different treatment protocols. ClAP pre-incubation partially separated proteasome assay
procedure from the ClAP treatment procedure.

Removal of ClAP after Treatment of the 20S Proteasome is Important to Characterize the
Full Effects of De-phosphorylation on the 20S Proteasome Activities

The commercial availability of agarose resin crosslinked ClAP enabled us to completely
separate the ClAP treatment procedure from the proteasome assay procedure. After treatment,
this resin could be easily removed from a reaction mixture by a simple centrifugation procedure.
The effect of ClAP resin treatment was consistent with previous data gained using recombinant
ClAP. P1 activity showed no change; P2 and p5 activities significantly induced. The dramatic
increase in p5 activity supported our hypothesis that recombinant ClAP could be a substrate of
20S proteasome and act as competitive inhibitor for p5 subunit activity assay. The further test this
hypothesis; A parallel experiment was conducted. The 20S proteasome was treated with
CIAP-agarose resin. This time, after removal of the resin, recombinant ClAP was added back to
the reaction mixture at time 0 of the 20S proteasome activity assay. As expected, in this parallel
experiment, the p5 activity increased at a significant lower magnitude compare to when the ClAP
was removed. In short, complete de-phosphorylation of the 20S proteasome with excess ClAP
significantly enhanced its trypsin-like (P2) and chymotrypsin-like (P5) peptidase activities, while
caspase-like activity was not significantly affected. However, recombinant ClAP could be
degraded by 20S proteasome and ClAP has the effect as a competitive inhibitor.of the p5 activity.
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Potential Kinases Which Regulates the 205 Proteasome Activities in vitro and in vivo

208 proteasome purified from murine heart was endogenously phosphorylated. This is

consistent with the finding from yeast and other mammalian tissues. The identification of kinases
and phosphatases involved is a critical step toward elucidating signaling cascades that regulate
208 proteasome activities. This would help us understand 208 proteasome functions in
physiological and pathological conditions and design specific pharmacological agents.
The improvement of mass spectrometry technologies makes systemic characterization of
208 proteasome associating kinases and phosphatases possible. The state-of-the-art mass
spectrometers have the ability to detect proteins at higher sensitivity than most protein dyes
commercially available. Taking advantages of the advance in technology, we identified CKII, PKA
and PP2A as 208 proteasome associating proteins. The identification of CK2 and PKA were
consistent with reports from other tissues and species. In a high-throughput yeast-two-hybrid study,
PP2A is suggested as a potential 208 proteasome interacting protein, while there is no previous
direct report on PP2A as endogenous 208 proteasome associating protein. In this study, mass
spectrometry and western blot confirmed that PP2A was one of the 208 proteasome associating
proteins.
Kinases and Phosphatases Coordinately Regulate the Activities of 205 Proteasome in vivo

As mentioned in previous section, CKII, PKA and PP2A were identified as 208 proteasome
associating proteins in murine heart. The regulation of 208 proteasome by these enzymes is an
important part of its biochemistry. PKA, CKII and PP2A all have been reported to have important
roles in cardiac physiology. PKA is a component of ~-adrenergic receptor cascade. CKII
participates in apoptotic pathway. PP2A has been reported to be involved in hypertrophy.
Both CKII and PKA phosphorylations increased 208 proteasome activities while PP2A
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showed the opposite effect. Both PKA and CKII belong to serine/threonine kinase family. PP2A is
one of the few serine/threonine phosphatases. Both PKA and CKII are serine/threonine kinases
and PP2A is serine/threonine phosphatase. ClAP is a member of another family of phosphatase,
alkaline phosphate. It is capable of removing serine, threonine and tyrosine phosphorylation in a
less

specific

manner.

The

ClAP

treatment

effect

suggested

there

are

more

kineases/phosphatases involved in 208 proteasome regulation. These enzymes were not
identified in the purified 208 proteasome preparation from Murine heart, probably due to less
affinity and/or lower stoichemistry to the 208 proteasome.
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Summary

205 proteasome has been proved to be phosphorylated in the murine heart by multiple
methods, including proteomic method, western blot and biochemical method. As a stable protein
complex with long half-life, phosphorylation modifications are necessary to accommodate this
mega-protease to signaling cascades.

Being the final and only executor of ubiquitin-proteasome system, 205 proteasome is
controlled by different signaling pathways. The complexity of murine cardiac 205 proteasome
phosphorylation profiles reflects this coordinated control scenario. Proteomic part of this study has
identified several kinases and phosphatase as 205 proteasome interacting proteins, including
CKII, PKA and PP2A, which are candidates controlling its phosphorylation profile and activities in
the murine heart. CKII and PKA have been reported as 205 proteasome associating proteins in
other tissue, but not in the heart. The studies of their impact on 205 proteasome activities are
incomplete and even controversial in the case of Ckll. PP2A has just been suggested in a
yeast-two-hybrid experiment as 205 proteasome associating protein. The functional impact of this
association has not been demonstrated at the tissue level before.

In this study, two approaches have been taken to study the regulatory roles of
phosphorylation on

murine cardiac 205 proteasome.

One approach was to globally

de-phosphorylated 205 proteasome with ClAP and observe its outcome. Further studies were
conducted to study the effect of particular kinases or phosphatase.

ClAP is a phosphatase with limited speCificity. Its treatment has been proved to remove
phosphate groups from 205 proteasome. There are two intriguing observations. This treatment
significantly enhanced 205 proteasome P2 subunit activity. Using different treatment protocols,
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pS

subunit activity was affected differentially. With the availability of agarose-linked ClAP, the
de-phosphorylation step and 20S proteasome activity assay step could be separated. This
documented global de-phosphorylation with ClAP increased both

P2 and p5 subunits activities and

ClAP were degraded by 20S proteasome.

Compared to global de-phosphorylation study, studies with specific kinases and phosphatase
are of more biological significance. PKA and CKII both are serine/threonine kinases. PKA is part of
~-adrenergic

receptor signaling cascade; CKII involves cell survival signaling. PP2A is a

serine/threonine phosphatase, and it has been suggested as a tumor suppressor. PKA and CKII
treatment both enhanced the peptidase activities of 20S proteasome. On the contrary, inhibition of
20S proteasome co-purifying PP2A also enhanced its peptidase activities. These results
uncovered the control of 20S proteasome and put it in the context of phosphorylation cascades,
which is important to study its role in cardiac physiology.
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Figure 10. ClAP Treatment Removes Phosphate Groups from Phosphorylated 20S
Proteasome. Purified murine cardiac 20S proteasome were treated with ClAP for 30min at 37°C
and then resolved with SDS-PAGE. Panel A. The gel was stained with phospho-protein specific
dye (Pro-Q Diamond from Molecular Probes). Compare to the non-ClAP treated 20S proteasome.
the 20S proteasome was de-phosphorylated by this treatment. Panel B. After Pro-Q Diamond
staining. the fluorescence from the gel was bleached with light and then the same gel was stained
with SYPRO Ruby total protein stain. The SYPRO Ruby stain pattern was not significantly different
between the ClAP treated and non-treated 20S proteasome.
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Figure 11. ClAP Treatment Selectively Increases 20S Proteasome Peptidase Activities.
Panel A. Purified murine cardiac 208 proteasome was co-incubated with both ClAP (Promega)
and subunit specific 208 proteasome substrates (Z-Leu-Leu-Glu-AMC for P1
Boc-Leu-8er-Thr-Arg-AMC for P2 subunit; 8uc-Leu-Leu-Val-Tyr-AMC for

subunit;

p5 subunit) at 37°C for

1hr. Proteasome activities were measured according to AMC fluorescence emission after it was
released from the recombinant peptides. ClAP treatment in this manner induced no significant
difference in P1 subunit activity, while P2 subunit activity was significantly enhanced and

p5

subunit activity inhibited. Panel B. Purified murine cardiac 208 proteasome was pre-incubated
with ClAP (Promega) at 3rC for 30min. Then subunit specific 208 proteasome substrates
(Z-Leu-Leu-Glu-AMC

for

Suc-Leu-Leu-Val-Tyr-AMC for

P1

subunit;

Boc-Leu-8er-Thr-Arg-AMC

for

P2

subunit;

p5 subunit) were added and the mixture were incubated at 37°C for

1hr. Proteasome activities were measured according to AMC fluorescence emission released from
the recombinant peptides. ClAP treatment in this manner induced no significant difference in P1
subunit activity, while both P2 and

p5 subunit activities were significantly enhanced.
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Figure 12. Removal of ClAP from the De-phosphorylated 20S Proteasome Increases the
Peptidase Activities Greater than When ClAP is Present. Panel A. Purified murine cardiac 20S
proteasome was pre-incubated with agarose-crosslinked ClAP (Sigma) at 37°C for 30min. ClAP
agarose was removed and subunit specific 20S proteasome substrates (Z-Leu-Leu-Glu-AMC for
131 subunit; Boc-Leu-Ser-Thr-Arg-AMC for 132 subunit; Suc-Leu-Leu-Val-Tyr-AMC for 135 subunit)
were added. The mixtures were incubated at 37°C for 1hr. Proteasome activities were measured
according to AMC fluorescence emission after it was released from the recombinant peptides.
ClAP treatment in this manner induced no significant difference in 131 subunit activity, while both 132
and 135 subunit activities were significantly enhanced. The increase in 135 subunit activity was
higher than that of 132 activity. Panel B. Purified murine cardiac 20S proteasome was
pre-incubated with agarose-crosslinked ClAP (Sigma) at 37°C for 30min. ClAP agarose was
removed and subunit specific 20S proteasome substrates (Z-Leu-Leu-Glu-AMC for 131 subunit;
Boc-Leu-Ser-Thr-Arg-AMC for 132 subunit; Suc-Leu-Leu-Val-Tyr-AMC for 135 subunit) were added
along with recombinant ClAP. The mixtures were incubated at 37°C for 1hr. Proteasome activities
were measured according to AMC fluorescence emission after it was released from the
recombinant peptides. ClAP treatment in this manner induced no significant difference in 131
subunit activity, while both 132 and 135 subunit activities were significantly enhanced. The increase
in 132 subunit activity was higher than that of 135 activity.
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Figure 13. Casein Kinase II Co-purifies with 205 Proteasome and Regulates Its Activities.
Purified murine cardiac 20S proteasome was incubated at 35°C with CKII in phosphorylation
buffer (50mM Tris-HCI, pH 7.5, 20mM MgCI2, 1mM OTT, 2mM ATP) for 15min. Then proteasome
peptidase activities were measured with fluorescently labeled recombinant peptide substrates. All
three peptidase activities were enhanced after the incubation.
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Figure 14. Phosphorylation of the 20S Proteasome by PKA Changes 20S Proteasome
Activities. Purified murine cardiac 208 proteasome was incubated at 35°C with PKA in
phosphorylation buffer (50mM Tris-HCI, pH 7.5, 20mM MgCI2, 1mM DTT, 2mM ATP) for 15min.
Then the proteasome peptidase activities were measured with fluorescently-Iabeled recombinant
peptide substrates. All three peptidase activities were enhanced after the incubation.
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Figure 15. Inhibition of the Murine Cardiac 205 Proteasome Co-purifying Protein
Phosphatase 2A Enhances Proteasome Peptidase Activities. Panel A. Purified murine cardiac

20S proteasome was incubated at 35°C with okadaic acid (inhibited 20S proteasome co-purifying
PP2A) for 30min. Then proteasome peptidase activities were measured with recombinant peptide
substrates. All three peptidase activities were enhanced after the incubation. Panel B. Purified
murine cardiac 205 proteasome was incubated at 3SoC with PP2A for 1Smin. Then proteasome
peptidase activities were measured with recombinant peptide substrates. P1 and pS subunit
activities were decreased after incubation.
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CHAPTER IV.

ASSOCIATION OF aB·CRYSTALLIN MODULATES 20S PROTEASOME ACTIVITES
Introduction

In the cell, 20S proteasome interacts with various proteins. These interactions regulate both
the activity and the subcellular localization of the 20S proteasome. Based on their distinct
biological functions, these 20S proteasome-associating proteins can be cataloged into different
groups. 19S, 11S and PA200 are well known as 20S proteasome activators (Coux, Tanaka et al.
1996; Bochtler, Ditzel et al. 1999; Glickman and Ciechanover 2002). They bind to either bottom of
20S proteasome and activate it by establishing a channel for substrate to access the proteolytic
core. Kinases and phosphatases belong to another group, which can regulate the 20S
proteasome by post-translational modifications (Pereira and Wilk 1990; Castano, Mahillo et al.
1996; Feng, Longo et al. 2001). They have been discussed in previous section. Members of heat
shock proteins (HSPs) have also been reported as 20S proteasome associating proteins(Conconi,
Petropoulos et al. 1998; Conconi, Djavadi-Ohaniance et al. 1999; Verma, Chen et al. 2000;
Boelens, Croes et al. 2001). The significance of such associations are not well understood.
Consistent with the nomenclature, HSPs are proteins that are upregulated in the cell after a
heat stress. Most of them are chaperones, which can prevent protein denaturation and/or help
denatured protein refold. The main families of HSP include HSP100, HSP90, HSP70, HSP60 and
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small HSPs (sHSPs). Proteins from different families vary both in sequence and functions. HSP60,
HSP70 and HSP90 are important for protein folding and maturation. HSP60 exists as multimer
and HSP70 as monomer and are both key chaperones involved in the folding of diverse proteins.
HSP90 monomer is important to maintain the native conformation limited set of proteins, most of
them are signaling proteins. sHSPs and HSPOO are primarily involved in stress response. The
former prevents protein denaturation and the latter rescues proteins for aggregation (Rutherford
2003).
sHSPs family has multiple members: alpha crystallin A (aA crystallin), alpha crystallin B (aB
crystallin), HSP 27, etc. They all have a homologous crystallin domain. aB crystallin and HSP27
expressed in the heart, while aA crystallin does not. aB crystallin over-expression protects the
heart against ischemia insult (Martin, Mestril et al. 1997; Latchman 2001; Rutherford 2003; Taylor
and Benjamin 2005).
PKC€ over-expression mouse line is a well-established cardio-protected model. Upon
ischemia insult, this model shows significant reduction of cardiac infarction (Pass, Zheng et al.
2001). As part of the effects to elucidate the mechanism for this protection, Dr. Ping's group
identifies 93 proteins within the PKCe subproteome combining the power of immuno-precipitation,
gel electrophoresis and mass spectrometry (Ping, Zhang et al. 2001; Vondriska, Klein et al. 2001).
In subsequent research, several members within this subproteome were studied. Kinases, such as
Lck, Src, Bmx, Erk; transcriptional factors, such as NFKB, AP1; mitochondrial proteins, such as
ANT, VDAC play roles in the protection (Ping, Zhang et al. 1999; Ping, Zhang et al. 1999; Li, Ping
et al. 2000; Ping, Song et al. 2002; Zhang, Ping et al. 2003; Zhang, Ping et al. 2004). However,
regulation of proteasome, the protein degradation machinery, was not covered by the previous
study. The PKCe subproteome study did not identify 20S proteasome subunits within these protein
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complexes. This could be the result of these subunits having similar molecular weight as the IgG
light chain, used in immuno-precipitation or their low abundance within these complexes.
Nevertheless, one of the well-known 20S proteasome binding proteins, aB crystallin, was shown
to be part of this subproteome.
This current study represents the first characterization of 20S proteasome within PKC&
over-expression, cardio-protected model. aB crystallin, as a stress-induced protein associating
with both 20S proteasome and PKC&, was screened for its potential as a 20S proteasome
regulator in the heart.
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Materials and Methods
Generation and Characterization of PKCETransgenic Mouse Lines

Standard techniques were used for the production and generation of PKCE over-expression
mouse. Briefly, a cardiac specific a-myosin heavy chain promoter was used to drive the
expression of PKCE cONA mutants in FVB/N mice. An HA tag was inserted into the 5' end of the
construct, which allowed differentiation of transgene expression from that of endogenous PKCE.
Constitutively active PKCE (AE-PKCE) is created by an A 159E mutation at the pseudosubstrate
domain. Mouse line expresses low level of the PKCE transgenic protein and is inherently protected
from cardiac ischemic injury. The phenotype of this transgenic mouse line has been previously
characterized.
Purified Murine Heart 205 Proteasome

10g of mice heart tissue was homogenized by a potter homogenizer in homogenize buffer
(Tris 20mM pH 7.8, EOTA 0.1 mM,

on 1mM,

with protease inhibitor cocktail from Roche and

phosphatase cocktails from Sigma). Cytosolic fraction was collected as the supernatant after 2hr
centrifugation at 25,000g. Cytosolic fraction was then fractionated by ammonium sulfate
precipitation. The pellet, collected between 40% to 60% ammonium sulfate saturation, was
re-suspended in 10ml dialysis buffer (Tris 20mM pH 7.4, MgCI2 5mM,

on

0.5mM).

Re-suspended fraction was dialyzed again 4L dialysis buffer overnight to remove ammonium
sulfate from it. The dialysate was fractioned with preparative-scale strong-anion-ion-exchange
column (Q FastFlow resin packed in XK 26/40 column from GE healthcare) by stepwise salt
concentration gradient elution at flow rate 5mllmin (45% B, until UV280nm monitor reading goes to
baseline; 75% B, collect 200ml; 100% B, until UV280nm monitor goes to baseline. Buffer A: Tris
20mM pH 7.4, MgCI2 5mM,

on 0.5mM, Glycerol 10%; Buffer B: Tris 20mM pH 7.4, MgCI2 5mM,
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on

O.SmM, Glycerol 10%, KCI 600mM). 7S% B fraction enriched in 20S proteasome. This

fraction was centrifuged at SoC 42,000rpm (Ti4S fixed angel rotor from Beckman) for 19hr. The
pellet

was

collected,

re-suspended

in

buffer

A

and

resolved

with

analytical-scale

strong-ion-exchange column (Mono Q HRS/SO from GE healthcare) with a linear salt concentration
gradient from 0% B to 100% B through 17.S column volume. The purified 20S proteasome was
recovered in fractions around 60%B.

2D-electrophoresis and LC-MS/MS

20 electrophoresis was conducted using Bio-Rad 11cm apparatus. Firstly, purified 20S
proteasome was desalted by TCA/Acetone precipitation. The desalted dry pellet was resuspended
and resolubilized with IPG rehydration buffer (7M urea, SOmM

on,

4% CHAPS, 0.2% 3-10

BioRad ampholytes). 11cm NL (non-linear) (BioRad) IPG was rehydrated in this solution overnight,
and then isoelectrofocusing was conducted with BioRad IEF cell (2S0V, linear gradient 20 min,
2S0V, step and hold Shrs, 3000V, linear gradient 1hr, 3000V, step and hold 1hr, BOOOV, linear
gradient 1hr, BOOOV, step and hold for a total of 4937S Vhrs.). After IEF, proteins in IPG strips were
reduced by 2%

on solution and alkylated by 2.S% IAA sequentially for 10 minutes each. The

second dimension electrophoresis was run with Bio-Rad pre-cast Criterion gel (12.S%) at 200V for
4Smin. The gel was fixed and stained with SYPRO Ruby protein dye (Molecular Probes).
Gel plugs stained by SYPRO Ruby were cut out with robotic gel cutter from Bio-Rad. Proteins
within these spot were digested with trypsin (Promega). The resulting peptides were resolved with
RP-HPLC column coupled online to a mass spectrometer (QSTAR from Applied Biosystems),
which would be able to generate mass spectra and search them against protein database,
identifying proteins within the original gel plugs.
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SOS-PAGE and LC-MS/MS

SOS PAGE was performed with Bio-Rad Mini-Protean II apparatus according to classic
laemmli protocol using 12.5% poly-acrylamide gels. Electrophoresis was conduced at 120V OC
for 1hr. After that, the gels were fixed and visualized by Colloidal Coomassie blue G-250 staining.
Gel plugs stained by Coomassie blue G-250 were cut out manually. Proteins within these spot
were digested with trypsin (Promega). The resulting peptides were resolved with RP-HPlC
column coupled online to a mass spectrometer (QSTAR from Applied Biosystems), which would
be able to generate mass spectra and search them against protein database, identifying proteins
within the original gel plugs.

Western-Blotting

Proteins resolved with SOS-PAGE were transferred in solution to nitrocellulose membrane
(Pall Life Sciences, O.45~M pore diameter). The transfer efficiency was checked by staining the
blot with Ponceau S (BioRad), which could be removed by Tris-Buffered Saline with 1% Tween-20
(TTBS) washing. The remaining procedure was as follows: Block the transblot with 5% milk for 1
hour; Probe with 1st antibody (1000X dilution in 5% milk, 1% Tween-20) for 1 hour; Wash with
TTBS (Tris-buffered solution with 1% Tween-20) for 3 times of 5 minutes each; Probed with
HRP-linked 2nd antibody (3000X dilution in 5% milk, 1% Tween-20) for 1hr; Wash with TTBS for 3
times of 5 minutes each; Finally the transblot was incubated with ECl reagent (GE healthcare) for
1 minute and chemiluminescent signal recorded with film (Kodak).

Immuno-precipitation

Hearts taken from 8 weeks old PKCE over-expression mice and wild type mice were
homogenized in buffer contains protease cocktail and phosphatase cocktail with potter
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homogenizer. Cytosolic fractions were collected by centrifuge at 100,000g for 1 hour. 300/lg
proteins from each of these fractions were pre-cleared by incubate with 20/l1 protein AlG beads
from Santa Cruz for 30 minutes at 4°C. Supernatants were recovered and incubated overnight
with 20/l1 protein AlG beads and 3/l1 primary antibody (0.2S/lg//lI) at 4°C. Beads were washed
three times for S minutes each with 1ml TTBS. Beads were then boiled with 200ul SOS PAGE
loading buffer for S minutes. Supernatants were collected and ready to use for subsequent SOS
PAGE and western blot study.

Fluorescent Peptide Substrates and 20S Proteasome Activities Assay

Z-Leu-Leu-Glu-AMC from Sigma was used to measure [31 subunit activity. (10X assay buffer:
2S0mM HEPES, pH 7.S; SmM EOTA; O.S% NP-40; 0.01% SOS). Boc-Leu-Ser-Thr-Arg-AMC from
Sigma was used to measure [32 subunit activity. (10X ssay buffer: 2S0mM HEPES, pH 7.S; SmM
EOTA; O.S% NP-40; 0.01% SOS). Suc-Leu-Leu-Val-Tyr-AMC from Bachem was used to measure
13S subunit activity. (10X assay buffer: 2S0mM HEPES, pH 7.S; SmM EOTA; 0.3% SOS).
Proteolytic activities of 20S proteasome were compared among heart samples from different
animal models (wild type mice, PKCE over-expression mice). 10/lg of protein from cytosolic
fraction of murine heart homogenate was used. The specific proteasome inhibitor, Epoxomicin
(Boston Biochem), was used in a parallel study as negative control for 20S proteasome activity
assay.

Statistical Analysis

All data are presented as Mean

± S.E.

Groups are compared using two samples t test for

unpaired data. A P value of less than O.OS was considered significant.
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Results
aB-Crystallin Co-purifies with 20S Proteasome from ICR Murine Heart

Purified murine cardiac 20S proteasome was resolved by 2D electrophoresis (Figure 16,
Panel A). The aB crystallin was identified within the 2D gel as a 20S proteasome associating
protein by mass spectrometry (QStar from Applied Biosystems). The spectra generated were
searched against IPI database using Mascot search engine (Matrix Science). 50% of aB crystallin
sequence was obtained and it's N-terminal was determined to be acetylated (Figure 16, Panel B).

PKCE Over-expression Mice have Increased Expression of 20S Proteasome Subunits;
While the Expression of 19S Subunits is Largely Unaffected

Proteasome subunits expression levels were compared between PKCE over-expression mice
and wild type control mice. This comparison was conducted with quantitative western blotting. The
expression levels of the 20S proteasome subunits a3, a 7 and p5 were significantly up-regulated in
PKCe over-expression mice (Figure 17, Panel A); on the other hand, the expression levels of the
19S proteasome subunits Rpt1 and Rpn2 showed no significant changes (Figure 17, Panel B).

20S Proteasome Peptidase Activities are not Significantly Altered in
PKCE Over-expression Mice

Peptidase activities of 20S proteasome within cytosolic fractions were compared among
PKCe over-expression mice and wild type control mice. The 20S proteasome specific inhibitor was
used to minimize proteolytic activities contributed from other intracellular proteases. Despite the
higher population of 20S proteasome subunits within PKCe over-expression mice, all three
peptidase activities of 20S proteasome showed no significant difference over wild type control
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mice (Figure 18).

aB-Crystallin Expression is Upregulated in PKC& Over-expression Mice

as crystallin

expression level was compared between PKC& over-expression mice and wild

type control mice with western blot. In the cytosolic fraction. PKC& over expression mice showed
small but significant up-regulation of as crystallin (Figure 19).

aB-Crystallin Immunoprecipitation, 205 Proteasome Western Blotting

The association between

as crystallin

and 205 proteasome was compared between PKC&

over-expression mice and wild type control mice by immuno-precipitate
protein

complexes followed with western

blot a7

as

subunit of 205

crystallin containing
proteasome.

The

chemiluminescent signal was significant stronger in PKC& over-expression mice compare to the
wild type mice (Figure 20). which suggests more 205 proteasome and

as crystallin association in

the transgenic mice.

205 Proteasome Immunoprecipitatlon, PKC& Western Blotting

The association between PKC& and 205 proteasome was also compared between PKC&
over-expression mice and wild type control mice. This was conducted by immuno-precipitation of
the 205 proteasome containing protein complexes followed with western blotting with PKC&. In the
PKC& over expression mice. more PKC& was present in the 205 proteasome containing protein
complexes (Figure 21).
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Discussion
aB-Crystallin Associates with 20S Proteasome

Consistence with previous study in other tissues, aB crystallin was also found to co-purify
with 208 proteasome from murine heart. In an in vitro study, a7 was suggested to be the subunit of
208 proteasome interacting with aB crystallin. This study in the heart provided further evidence
that the interaction between 208 proteasome and aB crystallin are ubiquitous among tissues.
As reported by Dr. Conconi (Conconi, Petropoulos et al. 1998; Conconi, javadi-Ohaniance et
al. 1999), purified latent rat liver 208 proteasome can be inhibited by aB crystallin, while activated
liver 208 proteasome can not. We were unable to reproduce this using in vitro biochemical
experiment with murine cardiac 208 proteasome. This could be due to the difference in the
biochemical properties between rat liver 208 proteasome and murine cardiac 208 proteasome, or
most likely due to variations in purification protocols. Nevertheless, the association between 208
proteasome and aB crystallin has been confirmed by immuno-precipitation experiments of this
study.

In PKCE Overexpression Mice, the Expression Level of 20S Proteasome Subunits
are Upregulated, but the Total 20S Proteasome Peptidase Activities
do not Change Significantly

This study presented the first characterization of proteasome regulation in a cardio-protected
phenotype, PKCE over-expression mouse line. Ubiquitin-proteasome system is responsible for the
turnover of the majority of intracellular proteins, among them, including lots of transcriptional
factors, signaling proteins. Proteasome is the final executer of this pathway. The contribution of its
regulation to accommodate a cardio-protected phenotype is sure of great significance.
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Three 20S proteasome subunit expression levels have been shown to be up-regulated in this
cardio-protected model; while the expression level of two 19S proteasome subunits showed no
significant difference. This is consistence with the fact that 20S proteasome subunits and 19S
proteasome subunits are under different transcriptional control mechanisms. Activation of NFKB
has been known leading to the up-regulation of 20S proteasome. Dr. Ping's group has reported

NFKB activation as one of the result of PKCE expression (Li, Ping et al. 2000). Even the 20S
proteasome subunit expression levels were increased in transgenic mice, its peptidase activities
showed no significant difference in non-stressed condition compare to the wild type mice. This
suggested there is an inhibitory mechanism within the transgenic model in such condition.

aB-Crystaliin is a Key Stress-response Protein Regulated in PKCE Overexpression Mice,
Which Associates with 20S Proteasome

aB crystallin is a member of sHSP family expression in the murine heart. Ubiquitin, key
component of ubiquitin-proteasome system, is also a heat-shock protein. aB crystallin is a
chaperone and its over-expression has been shown to be protective upon cardiac ischemic insult.
Indeed, in the cardio-protected transgenic mice, under non-stressed condition, there is a small but
significant up-regulation of aB crystallin expression level. Its protective effect has been attributed
to its ability to prevent protein denaturation. Even aB crystallin has been well known as 20S
proteasome associating protein, its potential of regulating 20S proteasome under stress has not
been tested.
As the first step to s,tudy the effect of aB crystallin regulating cardiac 20S proteasome in
resisting ischemic insult, their association has been compared between cardio-protected model
and wild type control. There are more 20S proteasome associating with aB crystallin in the
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protected model. Previous reports documented latent 208 proteasome could be inhibited with aB
crystallin, which would partially explain 208 proteasome inhibition in the protected model. 8uch
effect was not reproduced in vitro with purified cardiac 205 proteasome. This could be due to the
difference between the two 208 proteasome purification protocols.
In the Cardio-protected Mice, More PKC& Associates with 20S Proteasome

Immuno-precipitation study showed more PKC& was recruited to 208 proteasome containing
protein complexes in the cardio-protected model. In the purified murine cardiac 208 proteasome
preparation, however, PKC& was not shown as 208 proteasome associating proteins. aB crystallin,
as a well-known 208 proteasome associating protein, is recruited to PKC& subproteome in the
cardio-protected model. As reported in previous section, there are meanwhile significantly more
208 proteasome associating with aB crystallin in the cardio-protected model. This supported the
hypothesis proteins within PKCE subproteome regulated 208 proteasome activity. The availability
of aB crystallin mice enables us to test this in the near future.
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Summary

20S proteasome associating proteins have impacts on its functions.

as crystallin

is member

of sHSP family, well known associating with 20S proteasome. This has been confirmed by this
study in the murine heart. Significantly,

as crystallin

has also been reported playing a significant

role in cardio-protection against ischemialreperfusion injury.
PKCE over-expression mouse is a well-established cardio-protected model. Since it was
generated, extensive studies have been conducted to uncover the mechanisms that are
responsible for this phenotype. Several key proteins have been identified. These included
signaling proteins, transcriptional factors and apoptosis related proteins. However, protein
degradation and stability control pathway, specifically proteasome and heat shock proteins, have
been largely overlooked. This study represented a first report in this area.
In the transgenic cardio-protected mouse, the expression levels of 20S proteasome subunits
were significantly induced, while those of 19S proteasome subunits were un-affected. NFKS has
been showed as the transcriptional factor that induces the expression of 20S proteasome subunits.
This is consistence with previous report from Dr. Ping's group that NFKS was activated in this
transgenic model (Li, Ping et al. 2000). In spite of enhanced 20S proteasome expression level, its
peptidase activities showed no significant increase in transgenic mice. There must be certain
mechanism prevented this augment in transgenic mice.

as crystallin has been reported as a 20S proteasome aSSOCiating protein that could inhibit its
activity. The study showed only latent 20S proteasome, which is its in vivo conformation, could be
inhibited by

as crystallin, while the activated counterpart was

not affected by

as crystallin.

This

inhibitory effect was not reproduced with murine cardiac 20S proteasome. This could be explained
by that purified 20S proteasome was in an activated state. Nevertheless, the association between
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208 proteasome and aB crystallin was significantly enhanced in the transgenic model. In the
transgenic model, aB crystallin was recruited to PKCE subproteome compare to the wild type. In
this study, we have also seen increased association between 208 proteasome and PKCE. Proteins
within PKCE subproteome could be responsible for the inhibition of 208 proteasome in the heart.
The availability of aB crystallin transgenic mice would enable us to clarify this phenomenon in the
near future.
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Figure 16. a.B-Crystallin Co-purifies with 20S Proteasome from ICR Murine Heart. Panel A.

Purified murine cardiac 20S proteasome was resolved by 2D electrophoresis using Bio-Rad
apparatus. 2D gel was fixed, stained with SYPRO Ruby protein dye and image recorded with
Bio-Rad fluorescent imager. All spots shown on the gel were cut and proteins within them
identified with Qstar LC/MS/MS from Applied Biosystems. Panel B. Spectrum of a.B-Crystallin
N-terminal peptide acquired with Qstar LC/MS/MS, which is shown as underlineD balded red
character within its sequence. All other peptides with spectra recorded with the mass spectrometer
were shown as red underlined characters.
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Figure 17. PKCE Over-expression Affects Proteasome Subunits Expression Levels.
Proteasome subunit expression levels in the cardiac tissue cytosolic fractions were compared

between PKCE over-expression mice and wild type control mice by western blot. Panel A. 20S
proteasome subunits, a3, a7 and

~5,

were all upregulated in the transgenic mice. Panel B.

Expression levels of 19S proteasome subunits, Rpt1 and Rpn2, showed no significant difference
between transgenic mice and non-transgenic mice in non-stressed condition.
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Figure 18. 20S Proteasome Peptidase Activities are not Significantly Altered in PKCE
Over-expression Mice. 10119 of cytosolic fraction of heart homogenate were used in the

proteasome activity assays. LLE-AMC was used as substrate to evaluate

~1

activity; LSTR-AMC

was used to evaluate P2 activity; LLVY-AMC was used to evaluate p5 activity. After adding
substrates, the reaction mixtures were incubated 1hr at 37°C. The free AMC fluorescence was
measured using a fluorometer (excitation 390nm; emission 450nm). Parallel experiments were
conducted use 20S proteasome speCific inhibitor, epoxomicifl, to minimize background.
compare to WT. n=3 in all experiments. Data are expressed as mean±S.E.
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Figure 19. aB-Crystallin Expression is Up-regulated in PKCe Over-expression Mice.
Cytosolic fractions were recovered from supernatant after 1hour centrifugation at100,000g. The
expression level of aB-Crystallin was compared among PKCe over-expression mice and control
mice. Transgenic mice showed small but statistically significant up-regulation of as-Crystallin
expression level.
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Figure 20. Comparison of aB-Crystallin, 205 Proteasome Association. Association of aB
crystallin and 20S proteasome between PKCE overexpression mice and wild type control mice was
compared by immuno-precipitating aB crystallin containing protein complexes from the cytosolic
fraction followed by western blooting against the 20S proteasome a7 subunit. Transgenic mice
showed Significantly higher association.
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Figure 21. Comparison of PKCE, 205 Proteasome Association. Association of aB crystallin

and 20S proteasome between the PKCE over-expression mice and wild type control mice was
compared by immuno-precipitating 20S proteasome containing protein complexes from the
cytosolic fraction followed with PKCE western blotting. Transgenic mice showed significantly
higher association.
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CHAPTER V
SUMMARY AND DISCUSSION

The completion of Human Genome Project, the biggest achievement in basic biological
science within the last decade, provided us a blue print of human being, however, we are still far
from fully understanding it. Proteins serve as building blocks of life. They functions as cell
skeletons, enzymes, transporters, ion channels and hormones. Compared to -30,000 genes
identified and sequenced from Human Gnome Project, there are far more proteins being
generated by human, as results of alternative splicing and post-translational modifications.
Proteins are regulated at multiple levels, including alternative splicing, transcriptional control,
translational control, post-translational control, translocation and degradation. This thesis
represents a first comprehensive characterization of major component within murine cardiac
protein degradation pathway, 20S proteasome: composition, function and regulation.
Intracellular protein turnover mainly operates through two systems. The well-known lysosome
pathway, turnovers membrane proteins and pathogens. They are enclosed in a vesicle structure
called endosome. The fusion of endosome with lysosome exposes its content to lysosomal
proteases. The majority of nuclear and cytosolic proteins are turned over by proteasome related
pathways into peptides. These peptides are either transferred to cell surface as antigens or further
degraded by Tripeptidyl Peptidase II (TPP II) into amino acid to replenish cytosolic pool. Several
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proteasome-involved protein degradation mechanisms have been proposed. The elucidation of
poly-ubiquitin tagging pathway won Nobel Prize in Chemistry 2004. Ornithine decarboxylase and
cyclin 01 are targeted for 268 proteasome after binding to antizyme. Protein degradation by 268
proteasome independent of both ubiquitin and antizyme has also been reported. 208 proteasome
is known to degrade oxidative damaged proteins. It can turn over native proteins at in vitro setting.
Regulation of proteasome protein degradation process is complex. The regulation can be
accomplished selectively at protein substrate level.

Its ubiquitination, post-translational

modification and binding partner, impact its half-life. This regulation can also be achieved at
proteasome level. Its post-translational modification, associating partner and assembly de~ermine
its proteolytic activities and selectivity towards groups of substrates.
Establishment of large-scale 208 proteasome purification protocol from murine heart is a
pre-requirement for its characterization. Considering the nature of sample, cost, possibility of
genetic manipulation, biochemical method is optimal. The high stability, high molecular weight and
highly charged properties of 208 proteasome were utilized along the purification procedure to
reach a final purity higher than 95%. Moreover, 208 proteasome in the preparation has been
proved to be structurally intact and functionally active. Purified 208 proteasome was analyzed by
mass spectrometer after in-solution digestion or in-gel digestion following gel electrophoresis,
including 10 808 PAGE, 20 electrophoresis and blue native gel electrophoresis. All these
approaches have been proven to be complementary. 10 SOS PAGE provided higher
reproducibility, higher sample loading capacity and possibility of analyzing all proteins resolved
throughout one lane. 20 electrophoresis separated all 20S proteasome subunits, including
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post-translational modified subunits across the gel. This enabled us to analyze each subunit
individually and provides unique advantage when to identify post-translational modified residues.
Blue native gel electrophoresis resolved populations of 20S proteasome containing protein
complex while keeping them intact. Different species of 20S proteasome and its components could
be studied independently. Direct in-solution digestion skipped peptides extraction step, which was
mandatory for in-gel digestion procedure. High hydrophobicity peptides were difficult to extract.
In-solution digestion overcame this bias. As a result, all 17 subunits of 20S proteasome have been
identified, including 14 constitutive and 3 inducible subunits. Catching unique sequence within a
protein was sufficient for protein identification, however a high sequence coverage by mass
spectrometer was necessary for post-translational analysis. The pi of murine cardiac 20S
proteasome was 0.8 units lower than theoretical value, which suggested the existence of
post-translational modifications. Several subunits were represented with multiple focused spots in
2D gel. This fortified the idea that 20S proteasome was post-translational modified.
20S proteasome were phosphorylated endogenously. Both immuno-blotting and mass
spectrometric analysis showed purified 20S proteasome subunits were phosphorylated. As a first
study of such modifications, phosphorylations were removed globally by ClAP. ClAP treatment
enhanced 132 and 135 subunits activities significantly. Within

in vitro system, ClAP could also be

degraded by 20S proteasome serving as competitive peptidase assay inhibitor. PP2A, PKA and
CKII have been identified as murine cardiac 20S proteasome associating enzymes. PKA and CKII
could phosphorylate 20S proteasome to enhance its peptidase activities, while serine/threonine
phosphatase, PP2A, was a negative regulator of 20S proteasome activities.
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20S proteasome associating proteins can also regulate 20S proteasome. In PKCE
over-expression transgenic mice, 20S proteasome subunits, represented by a3, a? and P5, were
up-regulated. However, 19S subunits, represented by Rpt1 and Rpn2, showed no change.
Surprisingly, up-regulation of 20S proteasome subunits expression levels did not lead to its
significant activity change. 20S proteasome subunit and 19S subunits are under different
regulatory control. Dr. Ping's group reported PKCE activation induces NFKB, which has been
reported as 20S proteasome transcriptional activator. These over-expressed 20S proteasome
existed in a suppressed state to maintain an unchanged overall 20S proteasome activity in the
cytosol. aB crystallin is a small heat shock protein associating with and inhibiting 20S proteasome.
This association has been confirmed with heart sample in this study. aB crystallin is also a
component of PKCE subproteome. In the PKCE over-expression transgenic model, it is recruited to
PKCE subproteome compared to wild type control. In the transgenic model, increased association
of 20S proteasome with aB crystallin and PKCE subproteome was evidenced with
co-immuno-precipitation study.
aB crystallin knockout mice will be used as an important model to further study the functional
impact of this small heat shock protein over 20S proteasome. Murine cardiac 20S proteasome
from the transgenic models will be obtained and compared with that from the control model at
proteomic level. The regulation of relative population of proteasome species and its effect toward
phenotype are other important directions to follow.
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